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ABSTRACT 
Part 1: Dexamethasone is one of the most widely used drug molecules for the treatment of 
posterior segment ocular diseases. The major problems associated with the delivery of 
dexamethasone include its poor aqueous solubility and poor permeability into retinal tissues. 
Hence, we have conceptualized a transporter targeted prodrug approach to deliver 
dexamethasone to the inner retinal tissue following transscleral/subconjunctival 
administration. We have successfully synthesized and characterized peptide prodrugs of 
dexamethasone (valine-valine-dexamethasone and glycine-valine-dexamethasone). The 
aqueous solubility of both prodrugs was significantly higher than the parent drug. The 
prodrugs were recognized by peptide transporters present on the apical surface of MDCKII-
MDR1 cells. Although, the aqueous solubility of prodrugs was dramatically enhanced, their 
permeability across sclera and retina-choroid-sclera tissues was not compromised. 
Development of a sustained release nanoparticulate based formulation of val-val-
dexamethasone was challenging due to the leaching of the prodrug into the external aqueous 
phase during preparation. Hence, a hydrophobic ion pairing (HIP) complexation based 
approach was employed using dextran sulphate as the complexing polymer. Parameters of 
HIP complexation were optimized and later nanoparticles were prepared. A dramatic 
iv 
 
improvement in the encapsulation of prodrug was observed along with sustained release in 
the synthesized nanoparticles.  
Part 2: Development of a sustained release nanoparticulate based dosage form for protein 
therapeutics is a major challenge. These molecules rapidly denature in presence of organic 
solvents and sonication. Moreover, encapsulation of these molecules in polymeric matrix is 
poor due to their hydrophilic nature. HIP complexation cannot only enhance their 
encapsulation in nanoparticles but also confer conformation stability and steric protection to 
the complexed molecule. We have chosen two model proteins (Lysozyme and bovine serum 
albumin) and prepared their HIP complexes with dextran sulphate. Parameters for HIP 
complexation were optimized and protein containing nanoparticles were prepared. A 
significant enhancement in encapsulation of these molecules was observed in the 
nanoparticles. Nanoparticles were successfully characterized with respect to size, surface 
morphology and crystallinity of entrapped protein. The release of protein molecules was 
significantly sustained from nanoparticles. HIP complexation and method of nanoparticles 
preparation did not affect the structure (secondary and tertiary structure) and activity of the 
entrapped protein molecules.  
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CHAPTER 1 
LITERATURE REVIEW 
Modes of Administration and Barriers for Ocular Drug Delivery 
Compared with drug delivery to other parts of the body, ocular drug delivery has met 
with significant challenges posed by various ocular barriers. Many of these barriers are 
inherent and unique to ocular anatomy and physiology making it a challenging task for drug 
delivery scientists. These barriers are specific depending upon the route of administration viz. 
topical, systemic, and injectable. Most of these are anatomical and physiological barriers that 
normally protect the eye from toxicants. Moreover, various preformulation and formulation 
factors need to be considered while designing an ophthalmic formulation. Figure 1 represents 
important parts of the eye along with different routes of drug administration represented in 
italics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure of eye depicting anatomy and routes of administration  
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Topical Administration  
Topical administration, mostly in the form of eye drops, is employed to treat anterior 
segment diseases. For most of the topically applied drugs, the site of action is usually 
different layers of the cornea, conjunctiva, sclera, and the other tissues of the anterior 
segment such as the iris and ciliary body (anterior uvea). Upon administration, precorneal 
factors and anatomical barriers negatively affect the bioavailability of topical formulations. 
Precorneal factors include solution drainage, blinking, tear film, tear turn over, and induced 
lacrimation [1]. Tear film, whose composition and amount are determinants of a healthy 
ocular surface, offers the first resistance due to its high turnover rate. Mucin present in the 
tear film plays a protective role by forming a hydrophilic layer that moves over the 
glycocalyx of the ocular surface and clears debris and pathogens [2].  Human tear volume is 
estimated to be 7 μL, and the cul-de-sac can transiently contain around 30 μL of the 
administered eye drop. However, tear film displays a rapid restoration time of 2–3 min, and 
most of the topically administered solutions are washed away within just 15–30 s after 
instillation. Considering all the precorneal factors, contact time with the absorptive 
membranes is lower, which is considered to be the primary reason for less than 5% of the 
applied dose reaching the intraocular tissues [3]. 
In addition, various layers of the cornea, conjunctiva, and sclera play an important 
role in drug permeation. The cornea, the anterior most layer of the eye, is a mechanical 
barrier which limits the entry of exogenous substances into the eye and protects the ocular 
tissues. It can be mainly divided into the epithelium, stroma, and endothelium. Each layer 
offers a different polarity and a potential rate-limiting structure for drug permeation. The 
corneal epithelium is lipoidal in nature which contains 90% of the total cells in the cornea 
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and poses a significant resistance for permeation of topically administered hydrophilic drugs. 
Furthermore, superficial corneal epithelial cells are joined to one another by desmosomes and 
are surrounded by ribbon-like tight junctional complexes (zonula occludens) [4, 5]. Presence 
of these tight junctional complexes retards paracellular drug permeation from the tear film 
into intercellular spaces of the epithelium as well as inner layers of the cornea.  
The stroma, which comprises 90% of the corneal thickness, is made up of an 
extracellular matrix and consists of a lamellar arrangement of collagen fibrils. The highly 
hydrated structure of the stroma poses a significant barrier to permeation of lipophilic drug 
molecules. Endothelium is the innermost monolayer of hexagonal-shaped cells. Even though 
endothelium is a separating barrier between the stroma and aqueous humor, it helps maintain 
the aqueous humor and corneal transparency due to its selective carrier-mediated transport 
and secretory function [6]. Furthermore, the corneal endothelial junctions are leaky and 
facilitate the passage of macromolecules between the aqueous humor and stroma [7]. Thus, 
corneal layers, particularly the epithelium and stroma, are considered as major barriers for 
ocular drug delivery. It is vital to understand that the permeant should have an amphipathic 
nature in order to permeate through these layers.  
Compared to cornea, conjunctival drug absorption is considered to be nonproductive 
due to the presence of conjunctival blood capillaries and lymphatics, which can cause 
significant drug loss into the systemic circulation thereby lowering ocular bioavailability. 
Conjunctival epithelial tight junctions can further retard passive movement of hydrophilic 
molecules [8]. Certain amount of drug can also permeate across the sclera upon topical 
administration. Details about structures of sclera, choroid and retina have been mentioned in 
the coming sections.  
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Systemic (Parenteral) Administration 
Following systemic administration, the blood–aqueous barrier (BAB) and blood–
retinal barrier (BRB) are the major barriers for anterior segment and posterior segment ocular 
drug delivery, respectively. BAB consists of two discrete cell layers located in the anterior 
segment of the eye viz. the endothelium of the iris/ciliary blood vessels and the 
nonpigmented ciliary epithelium. Both cell layers express tight junctional complexes and 
prevent the entry of solutes into the intraocular environment [6]  such as the aqueous humor. 
BRB restricts the entry of the therapeutic agents from blood into the posterior segment. It is 
composed of two types of cells, i.e., retinal capillary endothelial cells and retinal pigment 
epithelium cells (RPE) known as the inner and outer blood– retinal barrier, respectively. 
RPE, located between the neural retina and the choroid, is a monolayer of highly specialized 
cells. RPE aids in biochemical functions by selective transport of molecules between 
photoreceptors and choriocapillaris. Furthermore, it maintains the visual system by uptake 
and conversion of retinoids [6]. However, tight junctions of the RPE efficiently restrict 
intercellular permeation. Following oral or intravenous dosing, drugs can easily enter into the 
choroid due to its high vasculature compared to retinal capillaries. The choriocapillaris are 
fenestrated resulting in rapid equilibration of drug molecules present in the bloodstream with 
the extravascular space of the choroid. However, the outer blood–retinal barrier restricts 
further entry of drugs from the choroid into the retina. Even though it is ideal to deliver the 
drug to the retina via systemic administration, it is still a challenge due to the BRB, which 
strictly regulates drug permeation from blood to the retina. Hence, specific oral or 
intravenous targeting systems are needed to transport molecules through the choroid into 
deeper layers of the retina [9] . 
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Oral Administration 
Oral delivery or in combination with topical delivery has been investigated for 
different reasons [10-12] . Topical delivery alone failed to produce therapeutic concentrations 
in the posterior segment. Also, oral delivery was studied as a possible noninvasive and 
patient preferred route to treat chronic retinal diseases compared to injectable route. 
However, limited accessibility to many of the targeted ocular tissues limits the utility of oral 
administration which necessitates high dosage to observe significant therapeutic efficacy. 
This can result in systemic side effects. Hence, parameters such as safety and toxicity need to 
be considered when trying to obtain a therapeutic response in the eye upon oral 
administration. A major prerequisite of the oral route for ocular applications is high oral 
bioavailability of the drug. Following oral absorption, molecules in systemic circulation must 
also cross the BAB and BRB. The function and barrier property of these protective ocular 
structures have been already discussed previously. 
Periocular Administration  
Although not very patient compliant, these routes are employed partly to overcome 
the inefficiency of topical and systemic dosing to deliver therapeutic drug concentrations to 
the posterior segment. Moreover, systemic administration may lead to side effects making it 
a less desirable delivery route for geriatric patients. The periocular route includes 
subconjunctival, subtenon, retrobulbar, and peribulbar administration and is comparatively 
less invasive than intravitreal route (See Figure.1 for the anatomical location of the sites of 
administration in the eye, represented in italics). The drug administered by periocular 
injections can reach the posterior segment by three different pathways: transscleral pathway; 
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systemic circulation through the choroid; and the anterior pathway through the tear film, 
cornea, aqueous humor, and the vitreous humor [13].  
Subconjunctival injection obviates the conjunctival epithelial barrier, which is rate-
limiting for permeation of water-soluble drugs. Thus, the transscleral route bypasses cornea–
conjunctiva barrier. Nevertheless, various dynamic, static, and metabolic barriers limit drug 
access to the posterior segment. Dynamic barriers include conjunctival blood and lymphatic 
circulation. Various authors reported rapid drug elimination via these pathways following 
subconjunctival administration [14-16]. As a result, the formulation is drained into systemic 
circulation thereby lowering ocular bioavailability. Thus, drug elimination from the 
subconjunctival space becomes a major determinant of the vitreous drug levels following 
subconjunctival administration. The molecules which escape conjunctival vasculature 
permeate through sclera and choroid to reach the neural retina and photoreceptor cells. It is 
important to understand the structural features and barrier properties of sclera, choroid and 
retina to design a successful transscleral drug delivery system. Hence in the following 
sections, we have briefly explained these details.   
Sclera: It is an elastic, microporous tissue which covers the entire globe except the 
cornea (area 16-17cm
2
). It mainly comprises of proteoglycans and collagen fibers. It mainly 
contains Type I collagen. Sclera contains aqueous pores and intracellular spaces through 
which many drug molecules can traverse. Compare to the other ocular tissues such as retina 
and cornea, sclera contains very few proteolytic enzymes. Sclera is relatively more 
permeable to drug molecules compared to the cornea. The permeability of various drug 
molecules across the sclera has been studied and reported in the literature. Various 
physicochemical properties of drug molecule affect its transport across the sclera such as 
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molecular radius, molecular weight and shape, etc. It is observed that as the size of the 
molecule increases the permeation across sclera decreases. Recent reports suggest that sclera 
is permeable to large molecular weight compounds such as IgG (150 kDa), bovine serum, 
albumin (66.3 kDa) and dextrans [17] . Molecular radius has been shown as a better predictor 
of scleral permeability compared to the molecular weight. Permeation of BSA (molecular 
radius: 3.62 nm) was found to be more across the sclera than the dextran of equivalent 
molecular weight (molecular radius: 4.5 nm). Other factors which influence the permeation 
of drug molecules across the sclera include hydration of the tissue, solubility (in water and 
lipid) and charge. Permeation across sclera increases with increase in hydration of tissue, 
water solubility and negative charge of the molecule [17, 18]. 
Bruch’s membrane-choroid: This is a vascular tunic part of the eye which supplies 
blood to the retina. There are some structural similarities between sclera and choroid. 
Choroid is also a matrix like structure made up of collagen. However, it also contains higher 
content of melanin. Various drug molecules were shown to bind with the melanin and affect 
disposition/pharmacokinetics of the drug molecule. Choroid poses a significant barrier for 
transport of drug molecule because of presence of lipidic plasma membrane of endothelial 
cells. Moreover, it is a highly vascularized tissue and hence it rapidly washes out the drug in 
the systemic circulation resulting in limited diffusion of drug into the retina. Some structural 
changes have also been reported in the Bruch’s membrane and choroid due to age. 
Hydrophilicity, molecular radius and charge are important determinants for the transport of 
drug molecule across choroid. 
 
8 
 
Retina: The retina is a multilayered membrane which mainly comprised of neural 
retina and retinal pigment epithelium (RPE). The main role of neural retina is signal 
transduction which leads to vision. RPE is a single layer of cuboidal cells which consist of 
tight intracellular junctions and acts as a barrier for transport of solute molecules. Upon 
transscleral administration, drug molecule has to cross the sclera, choroid and RPE in order 
to reach to the inner retinal tissues. The details about RPE have been mentioned in an earlier 
section. RPE acts as a barrier for drug molecules especially for hydrophilic drugs [19]. 
Various permeability studies have been performed to compare the transport of drug 
molecules across sclera and retina-choroid-sclera (RCS). These studied have shown higher 
permeability of drug molecules across sclera compared to RCS.  
Intravitreal Administration 
  Unlike periocular injections, the intravitreal injection offers distinct advantages as the 
molecules are directly inserted into the vitreous. However, drug distribution in the vitreous is 
non-uniform. Small molecules can rapidly distribute through the vitreous, whereas the 
diffusion of larger molecules is restricted. This distribution also depends on the 
pathophysiological condition and molecular weight of the administered drug [20]. The half-
life in the vitreous is another factor that can determine the therapeutic efficacy. Following 
intravitreal injection, the drug is eliminated either by the anterior route or posterior route. The 
anterior elimination route involves drug diffusion across the vitreous into the aqueous humor 
through zonular spaces followed by elimination through aqueous turnover and uveal blood 
flow. The posterior elimination pathway involves drug permeation across the blood–retinal 
barrier and requires optimum passive permeability or active transport mechanisms. As a 
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result, hydrophilicity and large molecular weight tend to increase the half-life of the 
compounds in the vitreous humor [9]. 
Transporters in Eye 
The traditional approach to improve ocular bioavailability is to modify the drug 
chemically to achieve the desired solubility and lipophilicity. However, a more rational 
approach would be a transporter-targeted modification of the drug. Transporters are 
membrane-bound proteins that play an important role in active transport of nutrients across 
biological membranes. The presence of transporters has been reported on various ocular 
tissues. These transporters may be amenable to bind and transport specific-targeted ligands 
attached to drug moieties.  
Two types of transporter systems are of interest in ocular drug delivery: efflux 
transporters and influx transporters. Widely studied efflux transporters belong to the ATP 
binding cassette superfamily, whereas influx transporters belong to the solute carrier (SLC) 
superfamily. Efflux transporters lower bioavailability by effluxing the molecules out of the 
cell membrane and cytoplasm. Prominent efflux transporters identified on ocular tissues 
include P-gp, multidrug resistance protein (MRP), and BCRP. Various authors reviewed the 
emerging role of transporters in ocular drug delivery [21-23]. P-gp has an affinity to efflux 
lipophilic compounds in normal as well as in cancerous cells, possibly leading to emergence 
of drug resistance. Expression and functional activity of P-gp was identified on various 
ocular cell lines and tissues such as the cornea [23-25], conjunctiva and RPE [26-30]. MRP 
works in a similar manner but effluxes organic anions and conjugated compounds. Out of 
nine known isoforms of the MRP family, only three were identified in ocular tissues. MRP2 
and MRP5 were identified in corneal epithelium [31, 32] whereas MRP1 was identified in 
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rabbit conjunctival epithelial cells [33]. RPE expresses MRP1 [34]. The presence of BCRP 
was also reported on the corneal epithelium [35]. Literature survey suggests that there has 
been a huge amount interest generated in last decade to screen  interactions of drug 
molecules with efflux pumps. Results of these studies play a significant role during selection 
of a lead compound. 
Influx transporters facilitate the translocation of essential nutrients and xenobiotics 
across biological membranes. These include carriers for amino acids, peptides, vitamins, 
glucose, lactate, and nucleoside/nucleobases. Stirred by the success of valacyclovir and the 
characterization of different influx transporters in ocular tissues, ophthalmic drug delivery 
scientists investigated various prodrugs targeting these influx transporters. Transporter-
targeted prodrugs offer multiple advantages. The prodrugs or analogues designed to target 
the influx transporters can significantly enhance the absorption of poorly permeating parent 
drugs, as these conjugates become substrates for the influx transporters and simultaneously 
evade the efflux pumps. Furthermore, physicochemical properties of the drug such as 
solubility and stability can be improved compared to the parent drug. Table 1 provides a 
summary of various transporter-targeted prodrugs investigated for drug delivery to various 
ocular tissues such as cornea, conjunctiva and RPE. 
The most commonly applicable influx transporters for ocular drug delivery are amino 
acid and peptide transporters. These proteins may have a putative role in ocular drug delivery 
along with their physiological role of transporting various amino acids and nutrients into 
ocular tissues. Amino acid transporters that belong to SLC1, SLC6, and SLC7 gene families 
were identified at the molecular level in ocular tissues, and their functional role was 
examined as well.  
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Table 1: Investigations carried out to evaluate transporter-targeted prodrug approach for 
ocular drug delivery 
 
 
OPT=oligopeptide transporter, SMVT=Sodium-dependent multiple vitamin transporter,  
B(0,+) = Amino acid transporter, GLUT = Glucose transporter, rPCEC = Rabbit primary 
corneal epithelial cells, HRPE= Human retinal pigment epithelium cells, RCS= Retina-
Choroid-Sclera, GCV=Ganciclovir 
Transporter system 
targeted- tissue/cell 
line 
Drug/Prodrugs 
Employed 
Observation Ref 
B(0,+) on the 
cornea  
L-aspartate acyclovir  
(L-Asp-ACV) 
Four fold higher transcorneal 
permeability of L-Asp-ACV compared to 
ACV 
[36] 
B(0,+) on the 
cornea  
Gamma-glutamate-ACV 
(EACV) 
Higher aqueous solubility of the prodrug 
along with the  transporter recognition 
[37] 
OPT system on the 
cornea  
L-valine acyclovir (L-
Val-ACV) 
Three fold higher transcorneal 
permeability of L-val-ACV compared to 
ACV 
[38] 
OPT system on the 
cornea  
Gly-Val-GCV, Val-Val- 
GCV and Tyr-Val- GCV 
Significant transcellular passive diffusion 
and transporter recognition resulted in  
higher AUC and Cmax 
[39, 
40] 
OPT system on  
rPCEC cells and 
cornea  
 
Val  and  Val-Val-
quinidine 
Prodrugs were not recognized by p-gp 
efflux pump and further found to be 
substrates of peptide transporters 
[41] 
OPT system on the 
retina 
 
Gly-Val-GCV, Val-Val- 
GCV, and Tyr-Val- 
GCV 
Two-fold higher RCS tissue permeability 
than that of GCV due to higher 
lipophilicity and translocation mediated 
by OPT across RPE 
[42] 
SMVT on the 
retina 
Biotin-GCV 
Higher biotin-GCV permeability into the 
retina-choroid and slower elimination 
from vitreous. 
[43] 
12 
 
 
Peptide transporters have been widely investigated for ocular drug delivery. Recently, 
Kansara et al from our laboratory have established the presence of peptide transporter on the 
basolateral side of the retina. This was a very significant development because these 
transporters can be targeted after transscleral/subconjunctival injection. Upon 
transscleral/subconjunctival injection drug can cross the sclera, choroid and finally 
recognized by the peptide transporters present on the basolateral side (Figure 2).  
 
Figure 2: A schematic representation of the transporter-targeted approach following 
transscleral administration of a prodrug molecule 
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Peptide transporters can translocate these prodrug molecules and eventually a 
significantly higher concentration of prodrug can be achieved inside the retinal tissue. This 
strategy can also be useful to target various drug molecules used for the treatment of 
posterior segment ocular diseases such as uveitis, macular edema, proliferative 
vitreoretinopathy, age related macular degeneration, etc. Kansara et al. have delivered 
ganciclovir by employing transporter targeted prodrug based approach [42]. They attached 
various amino acid (valine) and peptide moieties (valine-valine, glycine-valine, and tyrosine-
valine) with ganciclovir. These moieties were recognized by the peptide transporter due to 
the presence of amino acid/peptide moieties attached to drug molecule. These investigators 
have also performed transport studies across sclera and retina-choroid-sclera to find out 
permeability and compared it with the permeability of the parent drug (ganciclovir). The 
retina-choroid-sclera permeability values of valine-ganciclovir (3.29 +/- 0.09 x 10
-6 
cm/s), 
valine-valine-ganciclovir (4.14 +/- 0.33 x 10
-6 
cm/s), glycine-valine-ganciclovir (3.40 +/- 
0.47 x 10
-6 
cm/s) and tyrosine -valine-ganciclovir (3.08 +/- 0.29 x 10
-6 
cm/s) were two-fold 
higher than that of ganciclovir (1.61 +/- 0.06 x 10
-6 
cm/s). Higher permeability of the 
prodrugs across retina-choroid-sclera was attributed to the recognition and translocation by 
peptide transporters present on the basolateral side of the retina.  
Posterior Segment Ocular Diseases:  
Posterior segment ocular diseases include diabetic macular edema (DME), posterior 
uveitis (PU), diabetic retinopathy (DR), proliferative vitreoretinopathy (PVR), age related 
macular degeneration (AMD), choroidal neovascularization (CNV), etc.  Almost 10% 
patients having diabetes suffer from DME at some point of time in their life. More than 
75000 new cases of DME are registered every year in US alone. In a diabetic patient, blood 
14 
 
vessels of the retina start to leak the blood due to the damage and the fluid starts to 
accumulate in the macular region which eventually results in the complete loss of vision. 
DME is mainly classified in the two parts: (1) focal DME and (2) diffuse DME [44, 45]. 
Posterior uveitis is also one of the leading causes of vision loss in the US [46]. It starts with 
the inflammation of the choroidal vessels which supply nutrition to the photoreceptors in the 
retina. It progresses slowly and typical symptoms of the diseases are pain, floaters, light 
sensitivity and blurred vision. The cause of uveitis can be infection (due to virus, bacteria, 
fungus etc) or trauma. In diabetic retinopathy, blood vessels of the retina become leaky 
which causes the blurred vision and eventually results in complete loss of the vision.  AMD 
can be mainly divided into two parts (“Dry AMD” and “Wet AMD”) [47]. More than 10 
million people suffer due to AMD in US alone. The usual symptoms of dry AMD are 
breaking down of photoreceptors, RPE and choriocapillaris. However, the majority of vision 
threatening cases occurs due to wet AMD. In wet AMD, abnormal blood vessels grow 
beneath the retina which leads to the disruption of the Bruch’s membrane and RPE. The 
newly formed blood vessels are leaky hence leading to complete vision loss.  
Dexamethasone and Its Role in the Treatment of Posterior Segment Diseases 
Treatment of posterior segment ocular diseases such as macular edema, macular 
degeneration, proliferative vitreoretinopathy etc has been considered as a major challenge for 
ophthalmology scientists. These formidable diseases are chronic and vision threatening in 
nature.  
Dexamethasone (DEX, 9-fluoro-11β, 17, 21-trihydroxy-16α-methylpregna-1, 4-
diene-3, 20-dione) is one of the most widely used synthetic adrenocortical steroid for the 
treatment of posterior segment ocular diseases. Steroids such as dexamethasone, 
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triamcinolone acetonide, fluocinolone are among the most widely used therapeutic molecules 
for the treatment of these diseases. Dexamethasone has been traditionally used because of its 
anti-inflammatory, angiostatic, and anti-permeability properties. Dexamethasone also 
decreases intracellular and extracellular edema, suppress macrophage and lymphokine 
activity. Further, it inhibits angiogenic growth factors such as VEGF and other inflammatory 
mediators such as metalloproteinase and leucocytes. Due to these properties, dexamethasone 
is widely used in the treatment of posterior segment diseases.  
Mechanism of Action [48]  
Once the steroidal molecule reaches the cytoplasm within the target cell, it binds with 
the “glucocorticosteroid receptor” present in the cytoplasm. Later, this entire complex 
translocates inside the nucleus and binds with glucocorticosteroid responsive element (GRE) 
present on the glucocorticosteroid responsive genes. Figure 3 represents a classical model of  
anti-inflammatory actions of glucocorticosteroid.   
 
 
 
 
 
 
 
 
Figure 3: A schematic representation of the anti-inflammatory activity of glucocorticosteroid 
(GCS) [48] 
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Further, the steroidal molecule enhances the transcription of the genes which code for 
anti-inflammatory proteins. Steroidal molecules also directly inhibit expression of various 
inflammatory genes that regulate cytokines, enzymes and adhesion molecules. Apart from 
that, recent studies also suggest the direct effect of dexamethasone on chromatin structure 
which eventually results in tighter coiling of DNA and decrease in access of transcription 
factors to binding sites resulting in suppression of gene expression. 
Colloidal Dosage Forms for the Ocular Drug Delivery 
Colloidal dosage forms have been widely studied and employed in the field of ocular 
drug delivery [21]. These dosage forms include liposomes, nanoparticles, microemulsions, 
and nanoemulsions etc. Barriers to ocular drug delivery have already been described earlier 
in the context of structure and function of various ocular tissues and how each tissue can act 
as a barrier. The chronic nature of many ocular diseases necessitates frequent drug 
administration. Advantages of colloidal dosage forms include sustained and controlled 
release of the drug at the targeted site, reduced frequency of administration, ability to 
overcome blood–ocular barriers, and efflux-related issues associated with the parent drug 
[49]. Further, these carriers can also bypass or overcome various stability-related problems of 
drug molecules, e.g., proteins and peptides. Table 2 summarizes available literature on 
various formulations developed to sustain drug release via both the transcorneal and 
transscleral pathways. Designing an ideal delivery system for any ocular disease depends on 
molecular properties of the drug such as size, charge, and affinity towards various ocular 
tissues and pigments. 
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Table 2: Investigations carried out to formulate colloidal dosage forms of drug molecules for 
ocular drug delivery 
Formulation Characteristic of the formulation Ref 
Liposome 
 
Liposomal formulation of diclofenac was coated with low molecular 
weight chitosan which resulted in higher corneal permeation and better 
sustained drug release without any toxicity 
[50] 
Liposome 
 
Liposomal hydrogel formulation of gatifloxacin has sustained the drug 
release and enhanced transcorneal permeation 
[51] 
Liposome 
 
Liposomal formulation of sparfloxcain lactate has increased transcorneal 
permeation and antibacterial activity against S. aureus, P. aeruginosa, E. 
coli, and B. subtilis compared to free drug 
[52] 
Liposome 
Transcorneal permeation and intraocular distribution of GCV liposomal 
formulation was 3.9 fold and 2-10 fold higher, respectively, than GCV 
solution 
[53] 
Liposome 
 
Transcorneal permeation of demeclocycline was substantially higher and 
intraocular pressure was lowered for longer period of time 
[54] 
Nanoparticles 
 
Polymeric nanoparticles of Poly (D-L lactic-co-glycolic) acid and poly-
epsilon-caprolacton enhanced transcorneal permeability of flurbiprofen 
[55] 
Liposome and 
nanoparticles 
 
Both liposomal and nanoparticulate formulation sustained doxorubicin 
release across sclera. Drug release from liposome was slower than 
nanoparticles 
[56] 
Microparticles 
 
Following subconjunctival administration of PLGA microparticles, 
celecoxib levels were sustained and  inhibition of diabetes-induced 
retinal oxidative damage was observed 
[57] 
Microparticles 
and 
nanoparticles 
 
Following subconjunctival administration of PLGA nano and 
microparticles containing budesonide, drug levels were sustained in the 
retina for longer period of time 
[58] 
Collagen 
matrix 
 
Upon subconjunctival injection in rabbits, collagen matrix provided 
sustained release of cisplatin and resulted in a higher concentration in 
intraocular tissues 
[59] 
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Microemulsions 
Microemulsions are dispersions of water and oil facilitated by a combination of 
surfactant and co-surfactant in a manner to reduce interfacial tension. These systems are 
usually characterized by higher thermodynamic stability, small droplet size (100 nm) and 
clear appearance [60]. A review on application of microemulsions in ocular drug delivery by 
Vandamme et al., deals systematically with the various developments and challenges 
happening in the field. Selection of aqueous phase, organic phase and surfactant/cosurfactant 
systems are critical parameters which can affect stability of the system. Optimization of these 
components results in significant improvement in solubility of the drug molecule e.g. 
indomethacin, chloramphenicol [61]. Apart from solubility, microemulsion systems have also 
been exploited to improve permeation across the cornea. Though microemulsions have 
excellent advantages, limitations in selection of surfactant/co-surfactant system and potential 
toxicity associated with higher concentrations of surfactant/co-surfactant often restrict their 
use [62]. 
Nanosuspensions 
This can be defined as sub-micron colloidal system which consists of poorly water-
soluble drug, suspended in an appropriate dispersion medium stabilized by surfactants. 
Nanosuspenisons usually consist of colloidal carriers like polymeric resins which are inert in 
nature. They help in enhancement of drug solubility and thus bioavailability. Unlike 
microemulsions, they are also popular because of their non-irritant nature. Recently, three 
different types of glucocorticoids; hydrocortisone, prednisolone and dexamethasone were 
formulated as nanosuspensions. In vivo study in rabbits suggested that the nanosuspensions 
significantly enhanced the ocular absorption of glucocorticoids [63]. These nanosuspensions 
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also produce sustained drug release and were more effective over a longer period of time. 
Nanosuspensions may also impart stability to the drug in the formulation.  
Nanoparticles 
According to Sahoo et al., “Nanoparticles are defined as particles with a diameter of 
less than 1 μm, comprising of various biodegradable or non biodegradable polymers, lipids, 
phospholipids or metals” [64]. They can be classified as nanospheres or nanocapsules 
depending upon whether the drug has been uniformly dispersed or coated within polymeric 
material. 
Transscleral permeability of a compound depends on various parameters such as 
molecular weight, molecular radius, hydrophilicity, and charge of the molecule. Furthermore, 
the in vivo performance of colloidal dosage forms can be affected by size, dynamic barriers 
such as blood and lymphatic flow, affinity of the encapsulated drug towards melanin, and 
surface conjugation of nanoparticles with various endogenous molecules. Following 
periocular administration of nanoparticles, size plays a crucial role in determining the fate of 
the particles and the entrapped drug. Studies inferred that clearance of 20 nm particles by 
blood and lymphatic circulation was significantly higher, while 200 nm particles could be 
found at the injection site for over 2 months. Also, the study concluded that 20 nm particles 
were able to cross the scleral tissue to a very low extent, while 200 nm particles could not 
cross the sclera [65, 66]. Affinity of drug molecules towards melanin pigment present in the 
choroid-RPE also plays an important role in ocular disposition. Molecules having a higher 
affinity for melanin can bind to the pigment, and hence delivery to the inner retinal layers 
and the vitreous humor can be delayed [67]. Drug targeting by functionalization with some of 
the endogenous carrier molecules, which are natural substrates for a particular receptor or 
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transporter such as luteinizing hormone-releasing hormone agonist and transferrin, was 
successful. Disease conditions can also affect drug availability into the inner retinal tissues 
including Muller and photoreceptor cells [68]. In diabetes, disruption of the blood–retinal 
barrier can result in significant drug transport to the target site [68].  
Following intravitreal injection of a dosage form, the fate of colloidal carriers 
depends on numerous critical parameters. Vitreous humor is a colloidal fluid containing 
small amounts of solutes, ions, and low-molecular weight compounds. It mainly contains 
collagen (40–120 μg/mL) and hyaluronic acid (100–400 μg/mL). Due to negative charge of 
vitreal hyaluronan, positively charged molecules tend to aggregate in the vitreous humor. 
This was observed initially with the DNA lipoplex. Hence, it is very crucial to estimate the 
zeta potential of a colloidal dosage form under physiological condition [69]. PEGylation of 
particles can significantly minimize or avoid this problem to a large extent [70]. ILM is also 
known to restrict the movement of particles from vitreous humor to inner retinal layers. 
Achieving sustained drug levels from periocular administration is necessary for treating 
AMD, diabetic macular edema, and diabetic retinopathy. After subconjunctival 
administration, colloidal dosage forms (sizes up to 20 nm) and released drug molecules can 
be rapidly cleared by conjunctival, choroidal, and lymphatic circulations. Table 3 
summarizes available literature in this field. Various strategies have been employed to avoid 
clearance from these vasculatures.  
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Table 3: Characteristic features of colloidal dosage forms that affect their in vivo fate 
Factors affecting in 
vivo fate of 
nanoparticles (NPs) 
Important features and conclusion of the study Ref 
Size of NPs 20 nm NPs could not retain in the periocular site due to rapid elimination 
while 200 nm and 2 µm particles were detected after 2 months at the site 
of periocular injection in rats 
[65] 
Melanin pigment 
 
Transscleral transport of celecoxib was significantly higher in the 
Sprague-Dawley rats (Non-pigmented) than Brown Norway rats 
(pigmented). 
[67] 
Blood and 
lymphatic 
circulation 
 
Transport of 20 nm NPs across sclera was minimal due to rapid 
disposition in the presence of both blood and lymphatic circulations. 
Higher NPs size (200 nm) is required to avoid clearance via both 
circulations. 
[66] 
Diseases condition 
(diabetes) 
 
In diabetic rats, transscleral retinal and vitreal levels of celecoxib were 
significantly higher than non diabetic rats. Transscleral delivery in 
pigmented rats was higher than non-pigmented rats. 
[68] 
Functionalization of 
NPs 
 
Transport across cornea was enhanced due to functionlization of 
polystyrene NPs (20 nm) with deslorelin, a luteinizing hormone-releasing 
hormone (LHRH) agonist and transferrin. 
[71] 
Charge on the NPs 
 
Positive and negatively charged NPs were shown to distribute to the 
inner ocular tissues such as retina and vitreous humor following 
application of iontophoresis technique. Positively charged NPs have 
shown higher penetration than negatively charged NPs. 
[72] 
Charge on NPs 
 
Following intravitreal injection, anionic NPs were shown to distribute to 
the subretinal space and RPE in higher extent than cationic NPs. 
Endocytosis of NPs in Muller cells was also shown in the study. 
[73] 
Charge and 
pegylation  
After intravitreal injection of NPs, neural retina restricts the movement of 
NPs into RPE, which can be overcome by application of ultrasound 
[70] 
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Various naturally occurring polymers were studied as carriers for the nanoparticulate 
system. A formulation comprising dexamethasone acetate encapsulated in biodegradable 
PLGA nanoparticles was administered by the intravitreal route and the effect on CNV was 
studied. This study demonstrated a triphasic pattern of drug release. The drug level was 
found to be more than the level required to treat CMV [74]. In another study, mucoadhesive 
chitosan-sodium alginate nanoparticles were prepared and evaluated for topical delivery of 
gatifloxacin. This system resulted in burst release during the first hour followed by sustained 
release for 24 h. This approach helps in reducing the dosing frequency of the antibiotic 
because of the sustained action observed after single administration [75] . Moshfeghi et al., 
have extensively reviewed the perspectives of particulate delivery system (micro and 
nanoparticles) in ophthalmology [76]. Macugen
®
 was also entrapped in microspheres and 
studied following transscleral delivery. In vitro release study has shown release of macugen 
(2 μg/day) up to 20 days across the sclera. Inhibition of endothelial cell proliferation 
confirmed that biological activity was not affected by encapsulation [77].   
Liposomes  
Liposomes are lipid vesicles containing aqueous core which have been widely 
exploited in ocular delivery for various drug molecules. Various liposome based formulations 
were developed and delivered to treat both anterior and posterior segment diseases 
conditions.   
 
Intraocular Implants 
Implants have been widely employed to extend the release in ocular fluids and tissues 
particularly in the posterior segment. Implants can be broadly classified into two categories 
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based on their degradation property (1) biodegradable and (2) non-biodegradable. With 
implants, the delivery rate could be modulated by varying polymer composition. Implants 
can be in the form of solid, semi-solid or particulate based delivery systems [78]. These 
implants have been applied in the treatment of diseases affecting both anterior and posterior 
segments of the eye. The diseases include anterior segment disorders like glaucoma filtering 
surgery and posterior segment disorders like diabetic macular edema, posterior uveitis, 
proliferative vitroretinopathy, CMV retinitis, endophthalmitis, and posterior capsule 
opacification.  
Encapsulation of Small Hydrophilic and Protein Based Molecules in Nanoparticles 
  A wide variety of compounds with significantly diverse physicochemical properties 
have been developed in the last decade due to adaptation of combinatorial chemistry and 
high-throughput screening based approaches. Formulation development of such a diverse set 
of compounds poses a very significant challenge. Colloidal dosage forms have been 
introduced and widely investigated as drug delivery systems for both hydrophilic and 
hydrophobic molecules. Nanoparticulate based formulation approach has been very 
successful for the delivery of small and large molecules [18, 21, 79].  
The most widely used conventional methods of nanoparticle preparation include 
single (oil in water, O/W) and double emulsion (water in oil in water, W/O/W) methods. In 
single emulsion method of nanoparticle preparation (O /W emulsion), organic solvent is 
employed to dissolve small molecule along with polymer. In double emulsion method, 
hydrophilic drug molecule is initially dissolved in the aqueous phase and polymer is 
dissolved in the organic phase followed by sonication which results in a primary emulsion. 
Further, the aqueous phase is added and sonicated to obtain final W/O/W emulsion. 
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Sonication is employed in both the methods to reduce the size of the emulsion globules. 
Figure 4 represents the process which is used to fabricate nanoparticles using single and 
double emulsion methods [80].  
 
Figure 4: Preparation of nanoparticles using single (O/W) and double emulsion (W/O/W) 
methods [80].  
Since small molecules do not have complex secondary and tertiary structure such as 
proteins, they retain their biological activity when prepared using the abovementioned 
methods. However, the success of this approach has been limited to hydrophobic drug 
molecules. This is mostly because of higher entrapment efficiency and ease of formulation 
with conventional oil in water (O/W) and water in oil in water (W/O/W) emulsion methods. 
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However, these methods failed to provide similar entrapment efficiency in case of 
hydrophilic drug molecules because of rapid leaching of these molecules into the external 
aqueous medium [81-83]  (Table 4). Due to poor encapsulation, a large amount of polymer is 
required to encapsulate hydrophilic drug molecules. Some of the most widely used polymer 
such as poly-lactide-co-glycolic acid (PLGA) may chemically interact with the encapsulated 
drug and destabilize the drug molecule. This is true for many small molecules as well 
peptide/protein based molecules. Moreover, a higher amount of polymer would be required 
to inject in the human subject. Since these polymers are costly, it will also increase the total 
cost of the formulation.  
Delivery of protein based therapeutics has become a great challenge for scientists in 
the drug delivery field. Colloidal dosage forms of small peptide and protein molecules have 
been widely investigated to overcome absorption and stability related issues associated with 
macromolecules. However, success of this approach is mainly dependent on understanding of 
the formulation parameters. Macromolecules have a complex secondary and tertiary structure 
stabilized by various columbic and hydrophobic interactions which play a very crucial role in 
stabilization of their structure [84, 85]. These forces include various electrostatic interactions, 
hydrogen bond, Van der Waals forces, hydrophobic interactions, etc. An ideal method of 
formulation preparation would not affect the secondary and tertiary structure of the protein 
molecule. Usually, during nanoparticle preparation, secondary and tertiary structure of the 
protein is affected due to various organic solvents and physical stress arising from sonication. 
This might lead to denaturation of protein and loss in its biological activity. 
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Table 4: Investigations carried out to enhance encapsulation of small hydrophilic and protein 
based molecules in polymeric nanoparticles 
Drug 
molecule 
Issues associated with 
nanoparticles preparations 
Approach adapted  
Doxorubicin 
HCl 
 
Poor encapsulation in 
nanoparticles using SE and 
DE method due to higher 
affinity of drug for aqueous 
phase 
pH of drug solution was adjusted to 
increase its partition coefficient and 
drug molecule was made lipophilic. 
Drug entrapment was enhanced with 
decrease in burst release of drug  
[82] 
Insulin  Poor entrapment and rapid 
denaturation  
A novel solid in oil in oil (S/O/O) 
method was developed using DMF/corn 
oil as oil system. Insulin nanoparticles 
were successfully entrapped in PLGA 
microparticles.  In vitro and in vivo 
studies were conducted to ensure 
insulin activity. 
[86] 
Venlafaxine-
HCl 
 
Poor encapsulation using  
PLGA as a polymer 
Venlafaxine-HCl was encapsulated in 
heparin-immobilized pluronic/PVA 
composite microparticles.  Higher drug 
loading and sustained release of 
Venlafaxine-HCl was achieved.  
[87] 
Propranolol 
HCl 
 
Poor encapsulation using 
nanoprecipitation method  
Higher encapsulation efficiency was 
achieved using W/O/W emulsion 
method. Higher encapsulation was 
observed using PCL, PLGA and ethyl 
cellulose as polymer  
[88] 
Lysozyme 
 
Develop sustained/extended  
release formulation without 
affecting native structure 
Sustained and extended release of 
lysozyme was obtained from lysozyme-
SCIEO complex nanoparticles. 
Released lysozyme has regained its 
native activity. 
[89] 
Bovine serum 
albumin  
Poor encapsulation,  
denaturation and burst 
release 
Double emulsion pressure 
homogenization method was employed 
which resulted in higher encapsulation 
and sustained release 
[90] 
Tetuns toxoid, 
lysozyme and 
insulin  
Poor encapsulation and loss 
of activity of protein 
molecules 
Nanoprecipitation and emulsion based 
techniques were employed and 
compared. Higher encapsulation was 
achieved without affecting the protein 
structure. 
[91] 
 
SE: Single emulsion, DE: double emulsion, PLGA:Poly lactide-co-glycolide-acid, PVA: Poly 
Vinyl alcohol, SCIEO: sodium (sulfamate carboxylate) isoprene/ethylene oxide 
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Moreover, conventional methods of nanoparticle preparation such as single and 
double emulsion have failed to provide higher entrapment of peptide and protein molecules 
in nanoparticles (Table 4). Low entrapment is mainly because of leaching of these 
hydrophilic molecules into the external aqueous phase during nanoparticle preparation. These 
hydrophilic molecules exhibit higher affinity for external aqueous phase compared to 
hydrophobic polymeric matrix. Moreover, use of organic solvents and physical stress during 
homogenization often cause denaturation and irreversible aggregation of these molecules 
resulting in loss of their biological activity. The other major challenges for development of 
colloidal dosage forms for protein molecules include burst release and sometimes insufficient 
release from the nanocarriers. 
Role of Noncovalent Forces on Stability of Protein Molecules [92]  
Noncovalent forces play a crucial role in stabilization of secondary and tertiary 
structure of protein molecules. These forces include Van der Waals forces, hydrogen 
bonding, electrostatic interactions, hydrophobic interactions, etc. It is also important to 
understand the role of configurational entropy and solvent such as water on stability of 
protein molecules. A brief discussion about these forces has been mentioned below. 
Van der Waals interactions (London dispersion forces): These forces result from 
transient dipoles that nonbonded atoms induce in each other. These forces are weak in nature 
and only atoms with short distance can be involved. Primary structure and accessibility to 
water molecule also play a crucial role in how Van der Waals forces would affect the 
stability of the protein molecule. 
Hydrogen bond: These interactions arise from partial sharing of hydrogen atom 
between H bond donor and acceptor. OH and NH serve as hydrogen bond donors while 
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nitrogen and oxygen serve as hydrogen bond acceptors. In the protein structure, the peptide 
backbone and other polar amino acid side chains also serve as hydrogen bond donors and 
acceptors. A hydrogen bond is considered as a type of dipole-dipole interaction. Secondary 
structure of the protein (α helix and β sheet) originates from the hydrogen bonds in protein 
molecule.  
Electrostatic interactions: These interactions may occur between charged amino acids. 
Amino and carboxyl group of the side chain interact with each other resulting in electrostatic 
interactions. Protein molecules acquire native conformation based on electrostatic attraction 
and repulsion. 
 Configurational entropy:  Proteins have conformational entropy because of degree of 
freedom to protein side chains in unfolded state compared to native state. When an amino 
acid side chain is present on the surface, it would have higher flexibility than when it is 
buried in the core of the protein. It is observed that when the size of the protein is larger, 
there are greater numbers of side chain amino acids in the core of the protein thereby 
resulting in large conformational entropy. 
The role of water:  Water has a significant role in stabilizing the protein molecule. It 
can form H bond thereby stabilizes the protein structure. Buried amino acids such as 
tryptophan do not have access to water in the native state. In the unfolded/denatured stage, 
tryptophan comes in contact with water and results in the destabilization of the protein 
molecule.    
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Hydrophobic Ion Pairing (HIP) Complexation Approach  
Hydrophobic ion pairing (HIP) complexation method is a useful technique for 
delivery of protein and peptide molecules [93-95].  In this approach, an ionizable functional 
group of the hydrophilic drug molecule is stoichiometrically complexed with an oppositely 
charged group of a surfactant or polymer to form drug-surfactant or drug-polymer complex 
(Figure 5). Depending on the nature of the surfactant, HIP complex of the drug molecule 
exhibits significantly higher solubility in organic solvents along with dramatic reduction in 
its aqueous solubility[96]. 
 
 
 
 
 
 
Figure 5: Mechanism of HIP complexation between an ionizable functional group of drug 
molecule with oppositely charged surfactant/polymer molecule 
 
HIP complexation approach may provide many valuable benefits such as higher drug 
entrapment, transport across the biological membrane, sustained release and better enzymatic 
protection of the complexed drug [96, 97]. Most importantly, since a drug molecule is only 
ionically complexed, it can rapidly dissociate in the presence of oppositely charged ions [98]. 
Thus, this technique obviates the necessity of a covalent chemical conjugation of a drug 
molecule, which is tedious and often results in the loss of bioactivity especially in the case of 
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peptide and protein based therapeutics. HIP complexations of small molecules as well as 
peptide and protein based therapeutics have been already investigated for molecules such as 
leuprolide, mellitin and insulin [93, 94, 99].  
Advantages of HIP Complexation  
The higher aqueous solubility of a drug molecule is due to presence of the charge and 
also due to presence of a small counter ion. Using HIP complexation based approach; both 
these properties of a molecule can be manipulated in a reversible fashion. Based on chemical 
structure and reactivity of the counter ion, one can make a variety of HIP complex based 
compounds. Physicochemical properties of a HIP complex would vary based on the solvation 
ability of a counter ion. Moreover, solubility of HIP complex would also depend on the size 
and nature of the counter ion. The primary interaction between a drug molecule and a counter 
ion is due to the presence of ionic charge. Moreover, based on the structure, hydrophobic 
interactions might play a crucial role in the formation of HIP complex. HIP complex can be 
easily dissociated in the presence excess of oppositely charged ions in the medium. Hence, a 
drug molecule is only complexed with the counter ion in a reversible manner. A hydrophilic 
drug molecule exists as a hydrophobic moiety in the HIP complex and hence partitioning of a 
drug molecule can be enhanced significantly the organic phase with dramatic reduction in 
aqueous solubility. One of the crucial problems encountered in the encapsulation of 
hydrophilic is its higher affinity towards aqueous phase than the hydrophobic polymeric 
phase, which often results in poor encapsulation efficiency. HIP complexation of the drug 
enhances its affinity towards the polymeric phase and dramatically reduces its affinity for 
aqueous phase. Partition in the organic phase can be enhanced by several orders of 
magnitude. Hence, drug loading in the polymeric matrix can be significantly enhanced as 
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compared to the conventional methods. Due to HIP complexation of insulin, its octanol/water 
partitioning coefficient was enhanced 3000 fold without affecting its secondary and tertiary 
structure [96].   
Similarly, HIP complex can also enhance the permeation of ionizable drugs. 
Hydrophobicity of the HIP complex would be advantageous for enhancing the translocation 
through the biological membrane. Slower dissociation of the HIP complex would be 
beneficial in this case due to its slower dissociation, the HIP complex would have sufficient 
time to reach to the desired biological membrane.  
One of important goals of a colloidal dosage form is to sustain the release of the 
entrapped drug. Release of the drug molecule from the HIP complex also depends on the 
nature of the counter ion. During the nanoparticle preparation, HIP complex form of drug is 
encapsulated using another polymer such as PLGA. Hence release of the drug molecule will 
be dependent on the dissociation of drug from the HIP complex and diffusion of 
free/complexed drug from the polymeric matrix of PLGA. Drug delivery scientists can 
explore these strategies to sustain the release of the drug molecule at the desired site. Since 
the physicochemical properties of the complexed drug molecule depend on the nature of the 
counter ion, one can choose a polymer with higher molecular weight to further reduce the 
diffusion from the polymer matrix. This strategy would have a very crucial role in sustaining 
the drug release for the treatment of ocular diseases.  
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Table 5: Investigations carried out to formulate HIP complexes of protein molecules 
Drug molecule Surfactant used to 
prepare HIP complex 
Characteristic of the HIP complex  
Melittin 
 
Sodium dodecyl 
sulphate 
A significant enhancement in loading of 
Melittin in nanoparticles was observed. 
HIP complexation and nanoparticles 
preparation did not alter growth 
inhibitory effect of the protein. 
[94] 
Lysozyme 
 
Sodium oleate A significantly higher protein loading 
was obtained without altering secondary 
structure and conformation of the 
encapsulated protein.  
[98] 
Leuprolide 
 
Sodium oleate A microsphere based sustained release 
formulation was developed and activity 
of leuprolide was not altered 
[100] 
Leuprolide 
 
Sodium stearate A significant enhancement in loading of 
leuprolide in nanoparticles was observed 
along with the sustained release. 
[93] 
Insulin 
 
Sodium oleate Optimized formulation resulted in more 
than 90% insulin loading in 
nanoparticles. Insulin in nanoparticles 
was more effective in producing anti-
hyperglycemic activity.  
[99] 
sodium isoniazid 
methanesulfonate 
 
Alkyl trimethyl 
ammonium or tetra 
alkyl ammonium 
A significant decrease in solubility in 
aqueous phase along with enhancement 
in solubility in organic phase was 
observed. The slower dissociation of 
complex could allow enhanced 
portioning of the complex across 
biological barrier. 
[101] 
Insulin 
 
Sodium dodecyl 
sulphate 
HIP complex significantly enhanced 
partition in organic media along with 
maintenance of its secondary and tertiary 
structure. 
[102] 
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HIP complexation based approach could also provide significant benefits to deliver 
protein based therapeutics. In protein based therapeutics, lysine amino acids would be 
oriented on the outer surface which can be easily accessible for the oppositely charged 
surfactants or polymer molecules resulting in the formation of HIP complex. Protein based 
structures have complex secondary and tertiary structure which play an important role in 
structure stabilization and eliciting their biological response. Secondary and tertiary 
structures are stabilized by various electrostatic interactions, hydrogen bond, Van der Waals 
interaction and hydrophobic interactions etc. A counter ion should be selected in such a way 
so that the secondary and tertiary structure of the protein would not be destabilized. In the 
HIP complexation of a protein, the counter ions would bind with the lysine amino acids and 
restrict their conformation flexibility. In fact, protein structure can be stabilized using this 
approach.  Yoo et al. have studied the Tm of free lysozyme and lysozyme in the HIP complex 
form. Their result suggests that lysozyme in HIP complex form show more conformational 
stability compared to the free lysozyme. They observed higher Tm for lysozyme in HIP 
complexed form compared to the free form. Finally this technique would also obviate any 
covalent modifications in the primary structure of the protein to enhance its hydrophobicity. 
HIP complexation based approach has been investigated for various protein molecules (refer 
to Table 5 for summary). 
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PART IA: DESIGN AND EVALUATION OF PEPTIDE PRODRUGS OF 
DEXAMETHASONE FOR TREATMENT OF POSTERIOR SEGMENT OCULAR 
DISEASES PART IB: DEVELOPMENT AND CHARACTERIZATION OF 
NANOPARTICULATE FORMULATION OF A WATER SOLUBLE PRODRUG OF 
DEXAMETHASONE BY HIP COMPLEXATION. 
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CHAPTER 2 
INTRODUCTION 
Overview 
Treatment of posterior segment ocular diseases such as posterior uveitis, macular 
edema, proliferative vitreoretinopathy, macular degeneration etc., has been considered as a 
major challenge for ophthalmology scientists. These formidable diseases are chronic and 
vision threatening in nature. Dexamethasone is considered as a drug of choice to treat these 
diseases because of its anti-inflammatory, angiostatic, and anti-permeability properties. It 
decreases intra and extracellular edema, suppresses macrophage and lymphokine activity. 
Moreover, it inhibits angiogenic growth factors such as VEGF and other inflammatory 
mediators like metalloproteinase and leucocytes.  
However, delivery of dexamethasone to the posterior segment of the eye is a major 
challenge. Following topical administration, pre-corneal elimination due to lacrimation, tear 
dilution, corneal barriers (epithelium, stroma, and endothelium) and blood retinal barrier 
(BRB) severely hamper drug transport to the retina. BRB can be mainly classified into two 
parts: (1) inner and (2) outer BRB. The Outer BRB is formed by a single layer of retinal 
pigmented epithelial (RPE) cells, while the inner BRB is composed of endothelial blood cells 
which restrict the entry of a drug molecule from blood to inner retinal tissues. Oral and 
systemic routes of administration cannot deliver sufficient amounts of drug to the retina due 
to presence of inner BRB. Currently, intravitreal route has been widely accepted as an 
alternative route of drug delivery for steroidal molecules in the treatment of posterior 
segment ocular diseases. Numerous preclinical and clinical studies involving intravitreal 
injections and implants of various steroidal molecules (Posurdex
®
 for dexamethasone and 
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Retisert
®
 for fluocinolone acetonide) are reported in the literature. However major issues 
with the intravitreal route of drug administration are retinal detachment, endophthalmitis, 
vitreous hemorrhage, ocular deformities and patient incompliance. These drawbacks limit the 
use of intravitreal route to deliver drug molecules in the treatment of ocular diseases. 
Transscleral/subconjunctival route of drug administration has gathered a lot of 
momentum in recent times as an alternative route of drug delivery to the retina. Upon 
administration, drug molecules need to cross sclera, choroid and RPE in order to reach to the 
inner retinal layers. Various studies have compared the permeability of drug molecules 
across sclera and cornea. These studies have concluded that the sclera is comparatively more 
permeable than cornea. Transport of a drug molecule across sclera depends on many 
parameters such as molecular weight, molecular radius and charge of the molecule. Various 
studies have confirmed the importance of these parameters on transscleral diffusion of drug 
molecules. Transscleral route has been considered as a promising route due to its large 
surface area, ease of administration and relative high permeability (compared to cornea). 
Recent studies have concluded that the sclera is permeable to compounds having higher 
molecular weight such as IgG (Mol wt ≈ 150 kDa). Moreover, we have recently identified 
the presence of peptide transporters on the basolateral side of the RPE. These transporters 
can be targeted to deliver drug to the inner retinal tissues. Kansara et al. have prepared 
various dipeptide monoester prodrugs of ganciclovir and targeted these molecules to peptide 
transporters. They found significant enhancement in permeation of prodrugs across retina-
choroid-sclera (RCS) tissues. Enhanced transport was attributed to recognition of prodrugs 
by peptide transporters compared to parent drug which was not a substrate of the transporter. 
One of the crucial limitations to deliver dexamethasone is its poor aqueous solubility.      
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Transporter targeted prodrug approach can also be used to manipulate the physicochemical 
properties of the drug molecule. Prodrug strategy has been often employed to improve many 
physicochemical properties of drugs such as solubility, enzymatic stability, permeability, etc.    
Nanoparticles based formulation approach has been very successful for the delivery of drug 
molecules in the treatment of ocular diseases. Nanoparticles can protect the prodrug molecule 
from enzymatic degradation along with sustaining its release at the target site. However, 
encapsulation of hydrophilic prodrug molecule in polymeric nanoparticle is a challenging 
task. Conventional methods of nanoparticles preparation such as oil in water (O/W) and 
water in oil in water (W/O/W) emulsion methods have failed to provide higher entrapment 
efficiency of hydrophilic drug molecules. Poor entrapment is mainly due to rapid leaching of 
these hydrophilic molecules into the external aqueous medium. 
Hydrophobic ion pairing (HIP) complexation method is a useful technique for the 
delivery of protein and peptide molecules. In this approach, an ionizable functional group of 
the hydrophilic drug molecule is stoichiometrically complexed with an oppositely charged 
group of a surfactant or polymer to form drug-surfactant or drug-polymer complex, 
respectively. Depending on the nature of the surfactant or polymer, HIP complex of the drug 
molecule exhibits significantly higher solubility in organic solvents along with dramatic 
reduction in its aqueous solubility. Since the drug molecule exists as a hydrophobic moiety in 
the HIP complex, during nanoparticle preparation, it would preferentially partition into the 
hydrophobic polymeric matrix rather than the external aqueous medium. HIP complexation 
approach may provide many valuable benefits such as higher drug entrapment, transport 
across the biological membrane, sustained release and better enzymatic protection of the 
complexed drug. Most importantly, since a drug molecule is only ionically complexed, it can 
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rapidly dissociate in presence of oppositely charged ions. Thus, this technique obviates the 
necessity of a chemical conjugation of a drug molecule, which is tedious and often results in 
loss of bioactivity especially in the case of peptide and protein based therapeutics.  
This part of dissertation deals with synthesis and physicochemical characterization of 
hydrophilic peptide prodrugs of dexamethasone (valine-valine-dexamethasone and glycine-
valine-dexamethasone). Later, we prepared and characterized a sustained release 
nanoparticulate formulation containing HIP complex of valine-valine-dexamethasone with 
dextran sulphate. 
Statement of the Problem 
Dexamethasone is one of the widely used drug molecule for the treatment of posterior 
segment diseases. However, major delivery related issues associated with dexamethasone 
include its poor aqueous solubility and poor permeability to ocular tissue following topical 
and oral/systemic administration. Intravitreal route of drug administration results in severe 
side effects and hence design of a noninvasive strategy to deliver dexamethasone is of high 
clinical significance. Transporter targeted prodrug approach has been previously investigated 
to improve physicochemical properties of hydrophobic drug molecules. Dexamethasone is 
not a substrate of peptide transporter however by conjugating peptide moieties (valine-valine 
and glycine-valine); it can be targeted to peptide transporter present on the basolateral side of 
the retina. Hence, a novel peptide transporter targeted prodrug strategy can be designed to 
deliver dexamethasone following transscleral/subconjunctival administration.  
Moreover, development of a nanoparticulate based sustained release formulation of 
hydrophilic prodrug molecules is a challenging task. This is mainly due to poor entrapment 
of hydrophilic drug molecules in polymeric matrix of nanoparticles using single and double 
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emulsion methods. Due to hydrophilicity and higher water solubility, these molecules rapidly 
leach into external aqueous phase during nanoparticles preparation.  Hence, a novel approach 
should be designed to convert these hydrophilic, water soluble prodrug molecules into 
hydrophobic form. This approach should be designed in such a manner so that the inherent 
solubility of the prodrug molecule would not be compromised in irreversible manner. 
 
Objectives 
The objectives of this part of dissertation project are: 
(a) to synthesize and characterize peptide conjugates of dexamethasone (valine-valine-
dexamethasone and glycine-valine-dexamethasone) 
(b) to evaluate effect of chemical conjugation on physicochemical properties of prodrus 
such as solubility, buffer stability. 
(c) to study enzymatic stability of prodrugs in ocular tissue homogenates, characterize 
interaction of prodrugs with peptide transporters and evaluate their permeability across 
sclera and retina-choroid-sclera tissues. 
(d) to prepare and characterize a hydrophobic ion pairing (HIP) complex of valine-valine-
dexamethasone with dextran sulphate  
(e) to prepare nanoparticles of the HIP complex using PLGA as a matrix forming polymer 
(f) to characterize nanoparticles with respect to size, surface charge, surface morphology 
and  entrapment efficiency  
(g) to study and compare the release of valine-valine-dexamethasone from nanoparticles 
using different releasing media.  
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CHAPTER 3 
DESIGN AND EVALUATION OF PEPTIDE PRODRUGS OF DEXAMETHASONE FOR 
TREATMENT OF POSTERIOR SEGMENT OCULAR DISEASES 
Rationale: 
Treatment of posterior segment ocular diseases such as posterior uveitis, macular 
edema, proliferative vitreoretinopathy, macular degeneration etc., has been considered as a 
major challenge for ophthalmology scientists [18, 103, 104]. These formidable diseases are 
chronic and vision threatening in nature. Steroids such as dexamethasone, triamcinolone 
acetonide and fluocinolone are among the most widely employed therapeutic molecules for 
the treatment of these diseases [105-107]. Dexamethasone has been traditionally used 
because of its anti-inflammatory, angiostatic and anti-permeability properties [105-108]. It 
also decreases intra and extracellular edema, suppress macrophage and lymphokine activity. 
Moreover, it inhibits angiogenic growth factors such as VEGF and other inflammatory 
mediators such as metalloproteinase and leucocytes [109, 110]. Due to these properties, 
dexamethasone is considered as a drug of choice for the treatment of posterior segment 
diseases. 
However, delivery of dexamethasone to the posterior segment of the eye is a major 
challenge. Conventional routes of drug delivery such as topical (via eye drops) and systemic 
administration have failed to deliver therapeutic amounts of drug to the retina. Following 
topical administration, pre-corneal elimination due to lacrimation, tear dilution, corneal 
barriers (epithelium, stroma, and endothelium) and blood retinal barrier (BRB) severely 
hamper drug transport to the retina [18, 21]. BRB can be mainly classified into two parts (1) 
inner and (2) outer BRB.  Outer BRB is formed by a single layer of retinal pigmented 
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epithelial (RPE) cells, while inner BRB is composed of endothelial blood cells which restrict 
the entry of a drug molecule from blood to inner retinal tissues [18, 21]. Oral and systemic 
route of administration cannot deliver sufficient amounts of drug to the retina due to presence 
of inner BRB.  A large dose of systemically administered drug would be required to treat 
ailments of posterior segment. These large doses can cause undesired side effects which 
would severely affect patient compliance on long term therapy. Currently, intravitreal route 
has been widely accepted as an alternative route of drug delivery for steroidal molecules in 
the treatment of posterior segment ocular diseases. Numerous preclinical and clinical studies 
involving intravitreal injections and implants of various steroidal molecules (Posurdex for 
dexamethasone and Retisert for fluocinolone acetonide) are reported in the literature [111]. 
Implants release the drug molecule at a slow rate for a longer period of time. However major 
issues with the intravitreal route of drug administration are retinal detachment, 
endophthalmitis, vitreous hemorrhage, ocular deformities and patient incompliance [112]. 
These drawbacks limit the use of intravitreal route to deliver drug molecules in the treatment 
of ocular diseases. 
Transscleral/subconjunctival route of drug administration has gathered a lot of 
momentum in recent times as an alternative route of drug delivery to the retina. Upon 
administration, drug molecules need to cross sclera, choroid and RPE in order to reach to the 
inner retinal layers. Various studies have compared the permeability of drug molecules 
across sclera and cornea. These studies have concluded that the sclera is comparatively more 
permeable than cornea [113-115]. Transport of a drug molecule across sclera depends on 
many parameters such as molecular weight, molecular radius and charge of the molecule 
[116, 117]. Various studies have confirmed the importance of these parameters on 
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transscleral diffusion of drug molecules. Transscleral route has been considered as a 
promising route due to its large surface area, ease of administration and relative high 
permeability (compared to cornea). Recent studies by Ambati et al. have concluded that the 
sclera is permeable to compounds having higher molecular weight such as IgG (Mol wt ≈ 
150 kDa) [17]. Moreover, we have recently identified the presence of peptide transporters on 
the basolateral side of the RPE. These transporters can be targeted to deliver drug to the inner 
retinal tissues. Kansara et al have prepared various dipeptide monoester prodrugs of 
ganciclovir and targeted these molecules to peptide transporters [42]. They found significant 
enhancement in permeation of prodrugs across retina-choroid-sclera (RCS) tissues. Enhanced 
transport was attributed to recognition of prodrugs by peptide transporters compared to 
parent drug which was not a substrate of the transporter.  
So, in the present work, we hypothesized to design peptide prodrugs of 
dexamethasone which could be targeted to peptide transporters present on basolateral side of 
the RPE following transscleral/subconjunctival administration. Transporter targeted prodrug 
approach can also be used to manipulate the physicochemical properties of the drug 
molecule. Prodrug strategy has been often employed to improve many physicochemical 
properties of drugs such as solubility, enzymatic stability, permeability, etc [118, 119]. One 
of crucial limitation to deliver dexamethasone is its poor aqueous solubility. Earlier attempts 
have been performed to improve solubility of dexamethasone. Recently, da Silva-Cunha A et 
al. have formulated a microemulsion based system to increase solubility of dexamethasone 
[120]. They employed cremophore EL and other surfactants to improve solubilization of the 
drug. In another attempt, Khali RM et al. have prepared a nanosuspension of dexamethasone 
to improve its solubility. These authors have employed pluronic F-68 as a surfactant to 
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improve drug solubility [63]. Stefánsson et al. have prepared a cyclodextrin complex of 
dexamethasone to enhance its solubility. Further, these investigators have performed animal 
studies and found significant concentration of drug in the vitreous humor following topical 
administration [121, 122]. In the present manuscript, we have synthesized valine-valine-
dexamethasone (Val-Val-Dex) and glycine-valine-dexamethasone (Gly-Val-Dex). We 
characterized interaction of prodrugs with peptide transporters and studied effect of chemical 
modification on aqueous solubility of the parent drug. We also studied the buffer and 
enzymatic stability of prodrugs, their interaction with peptide transporters and cytotoxicity in 
ARPE-19 cells. Finally, transport study of drug/prodrugs was performed across sclera and 
retina-choroid-sclera (RCS) tissue.  
Material and Methods 
Dexamethasone was purchased from Biomol. Boc-valin-valine was obtained from 
CPC scientific. 1-[3-(dimethylaminopropyl]-3-ethylcarbodiimide (EDC) was obtained from 
Acros Organics. 4-Dimethylaminopyridine (DMAP) and tetrabutylammonium hydrogen 
sulfate (TBAHS) were purchased from Sigma-Aldrich. [
3
H]Glycylsarcosine (Gly-Sar) (4.0 
Ci/mmol) was procured from Moravek Biochemicals (Brea, CA). All the solvents and other 
reagents of analytical grade were purchased from local supplier and used as such without any 
purification. Distilled deionized water (DDW) was used to prepare buffer and mobile phase. 
Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12 (Ham) (1:1) (D-MEM/F12) and 
fetal bovine serum (FBS) were purchased from Gibco (Invitrogen Corporation, Grand Island, 
NY). For ex vivo transport studies across sclera and RCS, New Zealand white male albino 
rabbits, weighing 2–2.5 kg (Myrtle's Rabbitry, Thompson Station, TN) were used.  
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Synthesis of peptide prodrugs of dexamethasone  
 
Figure 6 : A schematic representation of synthesis of valine-valine-dexamethasone  
 
NMR data of Val-Val-Dexamethasone: Low melting solid; LC/ MS (m/z): 591.3;
  
1
HNMR (CD3OD): δ 0.81 – 0.83 (d, J = 7 Hz, 3H), 0.92 - 1.07(m, 18H), 1.47- 1.53 (m, 1H), 
1.72 – 1.59 (m, 2H), 1.86 – 1.83 (m, 1H), 2.46 – 2.15 (m, 5H), 2.71 – 2.64 (m, 1H), 3.01 – 
2.83 (m, 3H), 3.81 – 3.76 (dd, J = 8Hz, 12Hz, 1H), 4.21 – 4.24 (m, 1H), 4.53 – 4.48 (dd, J = 
5Hz, 12Hz, 1H), 4.98 - 5.14 (m, 2H), 6.05 (s, 1H), 6.24 – 6.27 (dd, J = 2Hz, 10 Hz, 1H),  
7.39 – 7.36 (dd, J = 2Hz,  10Hz, 1H). 
13
C NMR(CD3OD): 15.4, 15.6, 17.1, 18.1, 19.7, 23.8, 23.8, 29.0, 32.1, 32.3, 33.5, 35.6, 35.8, 
37.5, 41.6, 45.2, 59.2, 67.1, 70.3, 72.8, 73.2, 92.7, 101.7, 103.4, 125.2, 130.0, 156.0, 167.8, 
172.0, 172.6, 189.2, 206.3
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Figure 7: A schematic representation of synthesis of valine-dexamethasone 
 
NMR data of Val-Dexamethasone: Low melting solid; LC/MS (m/z): 492.7;  
1
HNMR (CD3OD): δ 0.85 – 0.87 (d, J = 7 Hz, 3H), 1.01(s, 3H), 1.16 – 1.19 (m, 9H), 1.50 – 
1.55 (m, 1H), 1.64 – 1.90 (m, 3H), 2.15 – 2.52 (m, 5H), 2.68 – 2.71 (m, 1H), 2.99 – 3.04 (m, 
2H), 4.04 – 4.05 (d, J = 4Hz, 1H), 4.24 – 4.27 (m, 1H), 5.13 – 5.14 (d, J = 5Hz, 2H), 6.08 (s, 
1H), 6.30 – 6.27 (dd, J = 2Hz, 10 Hz, 1H),  7.41 – 7.39 (d, J = 10Hz, 1H). 
13
C NMR (CD3OD): 14.0, 15.9, 16.8, 17.0, 22.4, 22.5, 27.6, 30.0, 31.0, 32.1, 34.2, 34.4, 36.1, 
36.2, 43.9, 58.1, 69.9, 71.3, 71.7, 91.3, 124.0, 128.7, 154.6, 168.7, 169.8, 187.8, 204.3 
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Figure 8: A schematic representation of synthesis of glycine-valine-dexamethasone 
 
Gly-Val-Dexamethasone: Low melting solid; LC/ MS(m/z): 549.1; 
1
HNMR(CD3OD): δ 0.84 
– 0.86 (d, J = 8 Hz, 3H), 1.00 - 1.22 (m, 12H), 1.50 - 1.90 (m, 6H), 2.18 - 2.50 (m, 4H), 2.67 
– 2.75 (m, 1H), 2.99 – 3.04 (m, 1H), 3.82 – 3.72 (m, 2H), 4.24 – 4.27 (m, 1H), 4.55 – 4.57 
(m, 1H), 4.94 - 5.02 (m, 2H), 6.08 (s, 1H), 6.27 – 6.30 (dd, J = 2Hz, 10 Hz, 1H),  7.40 – 7.42 
(m, 1H).  
13
C NMR (CD3OD): 15.3, 17.1, 18.1, 19.7, 23.8, 23.8, 29.0, 32.1, 32.4, 33.5, 
35.8, 37.5, 41.6, 45.2, 59.2, 70.3, 72.8, 73.1, 92.7, 101.7, 103.4, 125.2, 130.0, 156.1, 167.8, 
171.3, 172.5, 189.2, 206.3 
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The synthesis scheme to conjugate dipeptide moiety to various drug molecules has 
been previously published from our laboratory [40, 118]. Briefly, commercially available 
Boc-val-val-OH and EDC were taken in reaction flask 1 (mole ratio 1:1). The flask content 
were dissolved in dry DMF and stirred for 1 hr. In a separate reaction flask 2, dexamethasone 
and DMAP (mole ratio 1:1.5) were dissolved in DMF and stirred for 10 min at room 
temperature under inert atmosphere. The contents of flask 2 were added into flask-1 through 
a syringe in drop-wise manner and allowed to come to the room temperature and stirred for 
48 hrs. Small portion of the reaction mixture was taken out and injected in LC/MS to ensure 
the complete conversion of the starting material to product. The reaction mixture was filtered 
and filtrate was evaporated at room temperature under reduced pressure to get crude product 
Boc-val-val-dexamethasone. The product was purified by silica column chromatography 
using 5% CH3OH/CH2Cl2 as eluent. N-Boc-val-val-dexamethasone was treated with 80% 
TFA/CH2Cl2 at 0
o
C for 2.5 hrs to remove protecting group. Reaction mixture was evaporated 
under reduced pressure and the crude product was purified by cold diethyl ether precipitation 
to get the final product val-val-dexamethasone as a TFA salt. The prodrug was allowed to dry 
under vacuum before using it for the biological evaluation. Figure 6 contains the details of 
synthesis scheme of val-val-dexamethasone. 
To synthesize Gly-Val-Dex, we initially synthesized valine-dexamethasone (Val-
Dex). Commercially available Boc-Val-OH (110 mg, 0.51 mmol) was taken in to a reaction 
vessel. Dry DMF (10 mL) was added to dissolve it and it was cool down further to 0
o
C using 
ice bath. EDC (98 mg, 0.51 mmol) was added and stirred for 1h at same temperature. In a 
separate reaction flask, dexamethasone (100 mg, 0.25 mmol) was dissolved in DMF and 
further DMAP (47 mg, 0.38 mmol) was added to it. This reaction mixture was constantly 
48 
 
stirred for 10 min at room temperature under inert atmosphere to activate the primary 
hydroxyl group of dexamethasone. This reaction mixture was added into the previous 
reaction mixture using a syringe and stirring was continued for 48 h at room temperature. 
Small portion of the reaction mixture was taken out and inject in LC/MS to ensure complete 
conversion of the starting material to product. The reaction mixture was filtered and filtrate 
was evaporated at room temperature under reduced pressure to get crude product. The 
product Boc-val-dexamethasone was purified by silica column chromatography using 3% 
MeOH/CH2Cl2 as eluent with 87% yield. For deprotection of the NBoc group, compound 
Boc-val-dexamethasone was treated with 80% TFA/ CH2Cl2 at 0 
o
C for 2.5 h. The reaction 
mixture was then evaporated under vacuum. The final product was purified by 
recrystallization from cold diethyl ether to get the pure TFA salt of Val-Dex with an 
excellent yield (98%). To prepare Gly-Val-Dex, commercially available Boc-Gly-OH (405 
mg, 2.31 mmol) was taken in a reaction vessel along with Val-dexamethasone (700 mg, 1.15 
mmol) and triethylamine (TEA) (2 mL) was added to activate the primary amino group of 
Val-Dex. The product Boc-gly-val-dexamethasone was purified and deprotected in the 
similar way as mentioned earlier with 88% yield. The final product was achieved as a TFA 
salt after recrystallization from cold diethyl ether. Gly-Val-Dex was dried under vacuum 
before further evaluation was carried out. Figure 7 and 8 contains the details of synthesis 
scheme of val- dexamethasone and gly-val-dexamethasone. 
HPLC assay: 
HPLC method was developed for simultaneous analysis of VVD and dexamethasone. 
Waters 515 pump (Waters, Milford, MA) equipped with a UV detector (RAININ, Dynamax, 
Absorbance Detector Model UV-C) was employed for the HPLC analysis. A C18 column 
49 
 
was used as a stationary phase and water:acetonitrile (65:35; V/V) was selected as the mobile 
phase. VVD and dexamethasone were detected at 254 nm at the flow rate of 1 mL/min. We 
employed TBAHS dissolved in aqueous phase (10mM) as an ion pairing agent. The 
characteristic HPLC peaks of VVD (as a doublet) and dexamethasone are shown in Figure 9. 
Similarly, HPLC method was also developed to simultaneously analyze Gly-Val-Dex and 
dexamethasone. The characteristic HPLC peaks of Gly-Val-Dex and dexamethasone are 
shown in Figure 10.  
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Figure 9: The HPLC chromatogram of valine-valine dexamethasone and dexamethasone  
 
 
 
Figure 10: The HPLC chromatogram of glycine-valine dexamethasone and dexamethasone  
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Physicochemical Properties 
Aqueous solubility studies: 
Aqueous solubility study was performed by following previously published protocol 
from our laboratory [119].  Briefly, saturated solutions of dexamethasone and their prodrugs 
(Val-Val-Dex and Gly-Val-Dex) were prepared using 1 mL of distilled, deionized water in 
glass vials. These vials were then kept in shaker bath for 24 hrs at room temperature. After 
24 hrs, the content of the vial was carefully transferred in an eppendorf tube and centrifuged 
for 10 min at 12000 rpm. The supernatant was collected and filtered through 0.45 μm 
Nalgene syringe filter membrane. The supernatant was immediately stored in -20°C 
refrigerator until analysis was done using HPLC. This experiment was done in triplicate. 
pH stability studies:  
Chemical stability of dexamethasone prodrugs was carried out by following earlier 
published protocol from our laboratory [119]. Briefly, buffer solutions with pH of 1.4, 3.4, 
5.4, 7.4 and 9.4 were prepared and final pH was adjusted using NaOH/HCL within the range 
of ± 0.02 units. The buffer strength was 50 mM for all buffers. To initialize the study, 4.8 mL 
of buffer was taken in a glass vial and 200 µl of freshly prepared prodrug solution (3 mg/mL) 
in deionized water was added into it. The glass vials were kept in the water bath at 37°C and 
60 rpm. 100 µl of sample was taken at predetermined time interval. Samples were stored at 
−80 °C until analyzed by HPLC. This experiment was done in triplicate. 
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Ocular tissues hydrolysis 
Earlier published protocol was followed to separate the ocular tissues from New 
Zealand rabbits [123, 124]. Briefly, New Zealand white male albino rabbits were euthanized 
using sodium pentobarbital injection through the marginal ear vein. Both the eye balls were 
enucleated immediately and rinsed with pH 7.4 Dulbecco's Phosphate Buffered Saline 
(DPBS). Both ocular segments were carefully separated by putting an incision on the scleral–
limbus junction. Posterior segment ocular tissues such as conjunctiva, sclera, choroid-retina 
and vitreous humor were separated. These tissues were stored at −80 °C prior to use. These 
tissues were homogenized in an ice bath and homogenate was collected. Protein 
concentration of supernatant was measured using a BioRad assay. In all the stability studies, 
protein concentration of 0.5 mg/mL was employed. To initiate the study,    2.5 mL of 
supernatant was taken in a glass vial and 50 µl of prodrug solution (4.5 mg/mL of stock 
solution of prodrug) was added into it. At predetermined time interval, 50µl of sample was 
taken and immediately added into 50 µl of chilled methanol to terminate activity of enzymes. 
Samples were immediately centrifuged and supernatant was stored in −80 °C until analysis 
was done using HPLC. Finally, apparent first-order rate constants were calculated and 
corrected for any chemical hydrolysis observed with the control. This experiment was done 
in triplicate. 
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Cytotoxicity studies  
Cytotoxicity of dexamethasone prodrugs was evaluated in ARPE-19 cells using an 
aqueous non-radioactive cytotoxicity kit. This kit is based on the principle of MTS assay and 
has also been used in the past to study cytotoxicity of various prodrug molecules in our 
laboratory [125]. We chose ARPE-19 cell line for this experiment because of its human 
origin and its wide acceptance for in vitro work [126] . These cells were cultured by 
following earlier published protocol from our laboratory. Prior to the experiment, a fixed 
number of ARPE-19 cells (10000 cells/well) were plated in 96 well plate (Passage no 18) for 
24 hrs. After 24 hrs, culture medium was replaced with 100 µl of freshly prepared solutions 
of prodrugs (Val-Val-Dex and Gly-Val-Dex) and cells were incubated for 4h (in a 
humidified, 5% CO2 atmosphere). Both the prodrugs were tested in concentration range of 5, 
25, 50, 125, 250 and 500 µM. After 4 h, the above mentioned dye was added and incubated 
for 2 hrs. At the end of 2 h, cell viability was calculated using color determination at 485 nm 
using a 96 well microtiter plate reader (SpectraFluor Plus, Tecan, Switzerland). 5% triton X 
and culture medium were used as positive and negative control respectively.  
Interactions with PEPT 
This experiment was performed to investigate if peptide prodrugs can be recognized 
by the peptide transporters present on the apical side of MDCKII-MDR1 cells. Protocols for 
culturing MDCKII-MDR1 cells on 12 well plates and uptake experiments were previously 
published from our laboratory [125]. Briefly, once cells became confluent on 12 well plates, 
the uptake study was initiated by adding 1 mL of prodrug solution in presence and absence of 
competitive inhibitors. Gly-Sar, a well known substrate of peptide transporter was used for 
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this study. Uptake of [
3
H] Gly-Sar (0.75 μCi/mL) was studied in presence of unlabeled 
valine-valine (2.5mM), Val-Val-Dex (100 μM and 250 μM) and Gly-Val-Dex (100 μM and 
250 μM). Uptake study was carried out for 20 min at 37°C. At the end of 20 min, drug 
solutions were removed and washed with ice-cold stop solution (3 times). Further, cells were 
lysed with 1 mL of lysis buffer (0.1%, w/v, Triton X-100 in 0.3N sodium hydroxide) and 
kept at room temperature. Next day, 500 μL of aliquots were taken and transferred to 
scintillation vials containing 3 mL scintillation cocktail. Finally these samples were analyzed 
using a Beckman scintillation counter (Model LS-6500, Beckman Instruments, Inc.). Uptake 
was normalized to the protein content of each well. Protein content of cell lysate was 
quantified using BioRad protein estimation kit (BioRad, Hercules, CA). 
Transport studies of prodrugs across sclera and retina-choroid-sclera (RCS) tissue 
 Transport studies were performed to find out the permeability of dexamethasone and 
its peptide prodrugs across sclera and retina-choroid-sclera. These studies were done by 
following the protocol published earlier from our laboratory [42]. Briefly, New-Zealand 
white male albino rabbits weighing 2-2.5 kg were used in the study. Sclera and RCS tissues 
were separated after euthanizing rabbits as per earlier published procedure. Franz diffusion 
chamber apparatus was used for the transport studies. 1 mL of freshly prepared solutions of 
drug/prodrugs in pH 5 DPBS buffer was used as a donor while 5 mL of pH 7.4 DPBS buffer 
was filled in the receiver chamber. Transport of dexamethasone and its peptide prodrugs 
(Val-Val-Dex and Gly-Val-Dex) was carried out at equimolar concentrations (100 µM) for 3-
4 hrs at 37°C. 200 µl of sample was collected from the receiver chamber at predetermined 
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time intervals and replaced with DPBS buffer to maintain the sink conditions. All the 
samples were stored in -80 °C till analysis was performed using LC-MS/MS. 
Mass spectrometer analysis of prodrugs 
MDS Sciex API 2000 Triple Quadrupole linear QTrap mass spectrometry (Applied 
Biosystems/MDS Sciex, Faster City, CA) system interfaced by turbo ion spray (TIS) with 
positive ion source in MRM mode was used for detection. Mass dependent parameters were 
tuned and optimized for dexamethasone, Val-Dex, Val-Val- Dex, Gly-Val-Dex and 
hydrocortisone. Hydrocortisone was used as an internal standard (IS). Initially, full scan mass 
spectra were acquired in positive ion mode for all the compounds. During  a direct infusion 
experiment, the mass spectra for dexamethasone, Val-Dex, Val-Val- Dex, Gly-Val-Dex and 
hydrocortisone revealed peaks at mass to charge ratio (m/z) 393.20, 492.10, 591.00, 549.30 
and 363.20 respectively as protonated molecular ions [M+H]
+
. The most stable abundant 
fragment ions observed in each product MS/MS spectrum were at m/z 355.30 for DEX, 
373.20 for Val DEX, 171.20 for Val-Val-Dex, 129.00 for Gly-Val DEX, and 121.0 for IS. 
Quantitative determination was performed in MRM scan positive ion mode using the 
following mass transitions: 393.20→355.30 for DEX, 492.30→373.20 for Val- DEX, 
591.00→171.20 for Val-Val Dex, 549.30→129.00 for  Gly-Val DEX  and 363.20→121.0 for 
IS. The method was developed over the linear (r
2
 > 0.99) concentration range 11.0-650.0 
ng/mL. Lower limit of quantification (LLOQ) of all the compounds was 10.0ng/mL.  
Sample preparation and extraction 
Frozen samples were thawed at room temperature and thoroughly mixed using vortex. 
Using calibrated pipettes, 100 µL of samples were aliquoted into a 1.5 mL polypropylene 
microcentrifuge tubes (PPMCT). To these samples, we added 25 µL of 10.0 µg/mL freshly 
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prepared IS working solution (except for blank sample) and vortex mixed for 30 seconds. 
The samples were extracted by addition of 900 µL of methyl tertiary butyl ether (MTBE) 
followed by vortex mixed for approximately 2 min. After centrifugation at 12000 rpm at 4
0
C 
for 25 min, 850 µL of organic layer was transferred to a pre-labeled fresh 1.5 mL of PPMCT 
and evaporated in the Speed Vac® at 35
0
C for 60 min. The residue was reconstituted with 
100 µL of mobile phase, vortexed for 30 seconds and transferred into a pre-labeled HPLC 
auto-sampler vial with silanized inserts. 25 µL of the resulting solution was injected into LC-
MS/MS. 
Result and Discussion 
Dexamethasone is one of the most widely used drug molecule for the treatment of 
posterior segment eye diseases because of its anti-inflammatory and anti-permeability 
properties. However, delivery of dexamethasone to the posterior segment is challenging 
because of its poor aqueous solubility and permeability due to presence of tight junctions of 
RPE cells. So far, different approaches have been employed to enhance aqueous solubility of 
dexamethasone. In our laboratory, we have conceptualized transporter targeted delivery of 
dexamethasone. Our laboratory has confirmed the presence of peptide transporters on the 
basal side of RPE. Recently, Kansara et al., observed a significant enhancement in 
permeability of peptide prodrugs of GCV across RCS tissue due to recognition and 
translocation of the prodrugs by peptide transporters. By employing transporter targeted 
prodrug approach, one can also modify physicochemical properties of the drug molecule. 
Previously, we utilized this approach to overcome solubility, stability and permeability 
related issues of various drug molecules. Recently, transscleral/subconjunctival route has 
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gained a lot of momentum as an alternative to intravitreal route of administration. Hence, our 
long term objective was to develop, evaluate and deliver dexamethasone prodrugs via 
transscleral/subconjunctival route to treat posterior segment ocular ailments.     
We have successfully synthesized and characterized the peptide prodrugs of 
dexamethasone (val-val- dexamethasone and gly-val-dexamethasone) using 1H NMR and 
13C NMR. Solubility of the prodrugs was studied in distilled, deionized water. Solubility of 
both the prodrugs was significantly enhanced compared to the parent drug. This was an 
interesting observation because one would speculate decrease in the solubility due to 
conjugation of a peptide moiety with the parent drug. However, a dramatic enhancement in 
aqueous solubility was observed. Aqueous solubility values were 0.14 mg/mL for 
dexamethasone, 7 mg/mL for Val-Val-Dex and 4.9 mg/mL for Gly-Val-Dex, respectively 
(Table 6). Solubility enhancement was 50 and 35 fold for Val-Val-Dex and Gly-Val-Dex 
compared to the parent drug. We hypothesized two possible reasons for the higher aqueous 
solubility. One reason could be the salt form of the peptide prodrugs (both the prodrugs were 
obtained as TFA salt). The second possibility is that due to amorphous nature of the 
prodrugs, their aqueous solubility was significantly higher compared to the crystalline parent 
drug. XRD study confirmed that dexamethasone was crystalline in nature while prodrugs 
were amorphous in nature (Figure 11). Solubility enhancement could solve many delivery 
related issues associated with the parent drug. During a subconjunctival injection, a 
maximum of 0.5mL volume can be injected in the human subject [127, 128]. Due to higher 
solubility of the prodrug, a significantly higher dose can be given via subconjunctival 
injection compared to the parent drug (dexamethasone). Administration of higher dose may 
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result in higher flux across the scleral tissue and eventually higher drug levels could be 
achieved in the inner retinal tissues.  
Table 6: Aqueous solubility of dexamethasone, valine-valine-dexamethasone and glycine-
valine-dexamethasone  
 
 
 
 
 
 
 
 
 
 
Figure 11: X-ray diffractogram of dexamethasone, valine-valine-dexamethasone  
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Further, we studied the chemical stability of both the prodrugs in different pH buffers 
(pH 1.4 to 9.4). We did not observe any appreciable degradation of both the prodrugs at pH 
1.4.  As the pH increased, the degradation in different buffers was found to be higher. Table 
7 summarizes the apparent first order degradation rate constant indicating the loss of 
prodrugs. We also found that hydrolysis of the ester group was more critical and played a 
significant role in prodrug degradation. Val-Val-Dex was found to be more stable than Gly-
Val-Dex. This could be due to steric hindrance caused by the terminal valine group of Val-
Val-Dex towards hydroxyl ion attack on the ester bond. Due to steric hindrance, nucleophilic 
attack on Val-Val-Dex is less likely to occur than Gly-Val-Dex. These results were also in 
agreement with previously published stability data from our laboratory [129].  
Table 7 : First order rate constant k (10
-2
 × h
−1
) for prodrug degradation, representing the loss 
of prodrug, at different pH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ND: No significant degradation within the time of study 
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We also performed enzymatic stability studies of the prodrugs in presence of various 
posterior segment tissue homogenate. A prodrug molecule is pharmacologically inactive and 
hence would not exhibit any therapeutic effect unless it converts to the parent drug. Our 
findings suggest a rapid conversion of prodrugs into parent drug in all tissues. The rate of 
conversion of prodrugs into the parent drug was dependent on the type of tissue and presence 
of enzymes. The trend of bioreversion for both prodrugs was in the following order, choroid-
retina ˃ sclera ˃ vitreous humor. We have calculated the pseudo-first-order rate constants for 
the loss of Val-Val-Dex and Gly-Val-Dex in Table 8 and 9 respectively. During HPLC 
analysis, we have observed the peptide prodrug, its intermittent (amino acid derivative) and 
parent moiety as well. Rapid conversion of the prodrug into the parent drug was due to 
enzymes (esterase and peptidase) present in ocular tissues [130].  
Table 8 : First-order rate constants (10
-2
 × min
−1
) for the hydrolysis of valine-valine 
dexamethasone, representing the loss of prodrug in posterior segment ocular tissue 
homogenate of Albino rabbits  
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Table 9: First-order rate constants (10
-2
 × min
−1
) for the hydrolysis of glycine-valine-
dexamethasone, representing the loss of prodrug in posterior segment ocular tissue 
homogenate of Albino rabbits 
 
 
 
Both the prodrugs were studied for cytotoxicity studies in ARPE-19 cell line. 
Prodrugs were found to be nontoxic at all the concentrations studied (Figure 12 ). Triton X-
100 was used as positive control.  
 
 
 
 
 
 
 
 
 
Figure 12: Cell proliferation assay showing the percentage viable cells in presence of various 
concentrations of valine-valine-dexamethasone and glycine-valine-dexamethasone in ARPE-
19 cells  
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One of important objective of the present study was to target the peptide prodrugs to 
the peptide transporters. Recognition of prodrugs by peptide transporters may enhance their 
translocation within inner retinal tissues and eventually higher concentrations of the drug can 
be achieved at the target site. Hence, we performed uptake study using MDCKII-MDR 1 cell 
line. This cell line is widely used because it possesses tight junctions and it is also easy to 
culture [131]. Results of this study are shown in Figure 13. Both the prodrugs have shown 
significant reduction in uptake of [
3
H] Gly-Sar (100 µM and 250 µM concentration). This 
data suggest that both the prodrugs are recognized by peptide transporters and due to 
competitive inhibition uptake of [
3
H] Gly-sar was reduced. 
 
 
Figure 13: Uptake of [
3
H] Gly-Sar in presence of valine-valine with different concentrations 
of valine-valine-dexamethasone and glycine-valine-dexamethasone in MDCKII-MDR1 cells 
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Finally, we performed transport studies of dexamethasone and prodrugs across the 
sclera and retina-choroid-sclera tissue. Upon transscleral administration, drug molecule has 
to cross sclera, choroid and RPE to get into the inner retinal tissue. Transport of drug 
molecule across sclera depends on various physicochemical properties of the drug such as 
size, shape, charge, molecular radius etc. One of the major barriers for transscleral delivery is 
outer BRB which is formed by the tight junctions of the RPE cells. The RPE restricts entry of 
drug molecule into the inner retinal tissues. Recent studies have also identified various efflux 
pumps on the RPE, which efflux out drug molecules towards the choroidal side and 
eventually restrict the entry of drug molecules in retinal tissues. Moreover, in vitro studies 
have confirmed the recognition of prodrugs by peptide transporters present on MDCKII-
MDR1 cells. Therefore, we have hypothesized higher permeation of prodrugs across RCS 
tissue compared to parent drug. Permeability values of dexamethasone and peptide prodrugs 
across scleral and RCS tissues are shown in the Table 10.  
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Table 10: Permeability of dexamethasone, valine-valine-dexamethasone, glycine-valine-
dexamethasone across sclera and retina-choroid-sclera  
Permeability of all the compounds was dramatically reduced across RCS tissue 
compared to scleral tissue. These results confirmed that RPE acts as a barrier for the transport 
of drug molecules. We did not observe higher permeability of the prodrugs compared to the 
parent drug which could be due to rapid enzymatic bio-reversion of prodrugs into parent 
drug. Due to rapid bioreversion, prodrug molecules metabolized to parent drug 
(dexamethasone) before they could be recognized by the peptide transporter present on the 
RPE. In the past several attempts were carried out to enhance the permeability of the 
prodrugs which resulted in undesired reduction in aqueous solubility of the parent molecules. 
However in the present case, solubility of the prodrugs was enhanced compared to the parent 
drug without compromising their permeability across sclera and RCS. Solubility 
enhancement could have various beneficial implications for the delivery dexamethasone 
following transscleral/subconjunctival administration. A significantly higher dose of the 
prodrug can be administered in the conjunctival pocket compared to the parent drug. Since 
the permeability of prodrugs was not affected due to peptide conjugation, we have 
hypothesized to achieve a higher concentration of the drug at the target site following 
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transscleral/subconjunctival administration. Currently, studies are in progress to evaluate in 
vivo performance of these prodrugs in a rabbit animal model (data not included).  
Conclusion 
We have successfully synthesized dexamethasone prodrugs (Val- Val- Dex and Gly-
Val- Dex) and evaluated their physicochemical properties. Both prodrugs were shown to 
interact with peptide transporters present on apical side of MDCKII-MDR1 cells. Solubility 
of prodrugs was significantly enhanced than the parent drug dexamethasone (50-fold 
enhancement for Val-Val-Dex and 35-fold enhancement for Gly-Val-Dex). Solubility 
enhancement may lead to administration of a higher dose of prodrug molecule via 
transscleral/subconjunctival route. Even though, a dramatic enhancement in the solubility of 
prodrugs was observed, their permeation across sclera and RCS tissues was not affected. 
Prodrugs were found to be more stable at acidic pH compared to basic pH. All the prodrugs 
were rapidly converted to parent drug in all the tissues. Cytotoxicity study revealed that 
prodrugs were nontoxic at all the studied concentrations. Prodrug strategy may therefore be 
employed to improve physicochemical properties and overcome delivery related issues of 
other hydrophobic drug molecules.  
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CHAPTER 4 
DEVELOPMENT AND CHARACTERIZATION OF NANOPARTICULATE 
FORMULATION OF A WATER SOLUBLE PRODRUG OF DEXAMETHASONE BY 
HIP COMPLEXATION 
Rationale 
 A wide variety of compounds with significantly diverse physicochemical properties 
have been developed in the last decade due to the adaptation of combinatorial chemistry and 
high-throughput screening based approaches. Formulation development of such diverse set of 
compounds has become a very significant challenge. Colloidal dosage forms have been 
introduced and widely investigated as drug delivery carriers for both hydrophilic and 
hydrophobic molecules. Nanoparticulate based formulation approach has been very 
successful for the delivery of small and large molecules including the treatment of ocular 
diseases [18, 21]. So far the success of this approach has been limited to hydrophobic drug 
molecules. This is mostly because of higher entrapment efficiency and ease of formulation 
with conventional oil in water (O/W) and water in oil in water (W/O/W) emulsion methods. 
However, these methods failed to provide similar entrapment efficiency in case of 
hydrophilic drug molecules because of rapid leaching of these molecules into the external 
aqueous medium [81-83].  
Hydrophobic ion pairing (HIP) complexation method is a useful technique for the 
delivery of protein and peptide molecules [93, 96, 102]. In this approach, an ionizable 
functional group of the hydrophilic drug molecule is stoichiometrically complexed with an 
oppositely charged group of a surfactant or polymer to form drug-surfactant or drug-polymer 
complex, respectively. Depending on the nature of the surfactant or polymer, HIP complex of 
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the drug molecule exhibits significantly higher solubility in organic solvents along with 
dramatic reduction in its aqueous solubility [96]. Since the drug molecule exists as a 
hydrophobic moiety in the HIP complex, during nanoparticle preparation, it would 
preferentially partition into the hydrophobic polymeric matrix rather than the external 
aqueous medium. HIP complexation approach may provide many valuable benefits such as 
higher drug entrapment, transport across the biological membrane, sustained release and 
better enzymatic protection of the complexed drug [96, 97]. Most importantly, since a drug 
molecule is only ionically complexed, it can rapidly dissociate in the presence of oppositely 
charged ions [98].  Thus, this technique obviates the necessity of a chemical conjugation of a 
drug molecule, which is tedious and often results in the loss of bioactivity especially in the 
case of peptide and protein based therapeutics. HIP complexation of small molecules as well 
as peptide and protein based therapeutics has been already investigated for molecules such as 
leuprolide, mellitin and insulin [93, 94, 99].  
Dexamethasone is indicated for the treatment of posterior segment eye diseases such 
as macular edema, posterior uveitis and proliferative vitreoretinopathy. However, its delivery 
to the treatment of posterior segment eye diseases is a challenge because of poor aqueous 
solubility, susceptibility to efflux by P-gp and blood-retinal barrier [132]. Therefore, we have 
designed dipeptide prodrugs (PD) of dexamethasone such as valine-valine-dexamethasone 
(VVD) and glycine-valine-dexamethasone (GVD) to overcome these limitations. These 
prodrugs can be targeted to the peptide transporters present on the basolateral side of the 
retina [42]. The details about development of peptide conjugates of dexamethasone, their 
physicochemical characterization, interaction with peptide transporters and transport studies 
(across sclera and retina-choroid-sclera) are already mentioned before. Our long term goal is 
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to administer a nanoparticulate based formulation in the periocular space of the eye to sustain 
the release of VVD. Numerous studies have confirmed rapid endocytosis of nanoparticles by 
retinal cells [133, 134]. Aqueous solubility of VVD was about 50 times higher (7 mg/mL) 
than the parent drug dexamethasone (0.14 mg/mL). Higher solubility of VVD could be 
attributed to the presence of a terminal amino group and its amorphous nature. Initially, 
single and double emulsion methods were employed to prepare nanoparticles with poly (DL-
lactide-co-glycolide) (PLGA 85:15) as a polymer. Both methods resulted in nanoparticles 
with less than 10% entrapment of VVD (unpublished data).   
Therefore in this article, a novel HIP complex of hydrophilic, water soluble peptide 
PD (VVD) with dextran sulphate has been reported. VVD has one free terminal cationic 
amino group available which can undergo ionic complexation with anionic sulphate group of 
dextran sulphate. Dalwadi et al. have recently selected dextran sulphate as a complexing 
agent to enhance loading of hydrophilic and lipophilic drug molecules into pegylated PLGA 
nanoparticles [135]. In the current study, we have prepared and optimized HIP complexation 
of VVD with dextran sulphate. We also studied the dissociation phenomenon of VVD from 
HIP complex to understand the nature of interaction. Further, we investigated the effect of 
molar ratio of dextran sulphate to VVD and pH of aqueous medium of VVD on the 
complexation between VVD and dextran sulphate. The hydrophobic complex was not only 
insoluble in aqueous media but also found to be insoluble in organic solvents such as 
methylene chloride and acetonitrile. Hence, formulation using single emulsion (O/W) method 
was not feasible. Therefore, we employed solid/oil/water (S/O/W) emulsion approach for 
nanoparticles preparation using VVD in HIP complex form and evaluated formulation 
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parameters. Later, nanoparticles were characterized for particle size, zeta potential, XRD, 
surface morphology (using SEM and TEM), entrapment efficiency and drug release profile.  
Materials and Methods: 
Materials: Dexamethasone was obtained from Biomol. Boc-valin-valine was obtained from 
CPC scientific. 1-[3-(dimethylaminopropyl]-3-ethylcarbodiimide (EDC) was obtained from 
Acros organics. 4-Dimethylaminopyridine (DMAP), Dextran sulfate sodium salt (average 
molecular weight 9000-20000), Poly (DL-lactide-co-glycolide)(PLGA 85:15, average 
molecular weight of 50,000-75,000), Polyvinyl alcohol (PVA) and tetrabutylammonium 
hydrogen sulfate (TBAHS)  were purchased from Sigma Aldrich. All solvents and other 
reagents of analytical grade were purchased from a local supplier and used as such without 
any purification. Distilled deionized water (DDW) was used throughout the study. 
 
Synthesis and HPLC method development of val-val-dexamethasone:  
The details about synthesis and HPLC method development are already mentioned 
earlier (Figure 6 and 9) 
 
General preparation method of HIP complex between VVD and dextran sulphate  
Formation of HIP complex between VVD and dextran sulphate was a single step 
process. Briefly, aqueous solutions of VVD and dextran sulphate were prepared separately 
with DDW. To form the HIP complex, aqueous solution of dextran sulphate was added to the 
aqueous solution of VVD. Once both the aqueous solutions were mixed and vortexed, HIP 
complex formed instantaneously. The complex was separated by centrifugation at 10000 
RPM for 10 min. The supernatant was isolated and analyzed to measure the uncomplexed 
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free VVD by HPLC.  Percentage complexed VVD was calculated with the following 
equation 1. 
% Complexed VVD = [(Initial amount of VVD – amount of VVD in supernatant)/ Initial 
amount of VVD)] *100                                 ( Eq.1.) 
 
Effect of molar ratios of dextran sulphate to VVD on complex formation:  
  HIP complexes were prepared by varying molar ratios of dextran sulphate to VVD. 
An aqueous solution of dextran sulphate was added to VVD solution in different ratios to 
form the HIP complex. Various molar ratios of dextran sulphate/VVD were studied such as 
0.003, 0.007, 0.014, 0.029 and 0.058. The solution was centrifuged to obtain clear 
supernatant followed by HPLC analysis to measure uncomplexed VVD.  
 
Effect of pH of aqueous solution of VVD on HIP complex formation 
An aqueous solution of VVD was prepared and the pH was adjusted to 4.5, 5.5, 6.5, 
7.5 and 8.5 using 0.1 M NaOH. Dextran sulphate solution was added to the VVD solution to 
form the HIP complex (molar ratio of dextran sulphate/VVD 0.014).  Uncomplexed VVD 
was measured in the supernatant using the above mentioned process.  
 
Dissociation of the HIP complex 
Dissociation of the HIP complex was also studied to understand the nature of 
complexation between dextran sulphate and VVD. For this study, initially the HIP complex 
of dextran sulphate and VVD was prepared in the molar ratio of 0.014. The HIP complex was 
separated from uncomplexed prodrug by centrifugation. Later, the complex was redispersed 
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with DPBS solution having different concentrations of NaCl (10 mM and 100 mM) and 
DDW. These solutions were kept for equilibration for a period of 2 hrs at 37 °C using a rotor. 
Following equilibration, the HIP complex and VVD were separated by centrifugation and 
uncomplexed VVD was measured by analyzing the supernatant. 
 
Preparation of nanoparticles by solid/oil/water emulsion method 
 
Five mg of VVD in the form of HIP complex was used for the preparation of 
nanoparticles. Three mL of methylene chloride was added gradually to the complex and the 
mixture was vortexed for 2-3 minutes. Various ratios of VVD: PLGA 85:15 were employed 
to prepare the nanoparticles such as 1:10, 1:15 and 1:20. PLGA 85:15 was dissolved 
separately in 4 mL of methylene chloride. This solution was gradually added to the earlier 
prepared dispersion containing HIP complex. Parameters such as total volume of methylene 
chloride and vortexing time were optimized to obtain a S/O dispersion. About seven mL of 
methylene chloride was required to completely disperse the HIP complex. Later, sonication 
was performed for about 2-3 minutes using tip sonicator (Fisher 100 sonic dismembrator, 
Fisher Scientific) at a constant power output of 25 W to obtain the fine S/O dispersion. To 
this S/O dispersion stored in ice, external aqueous phase (30 mL, 1% PVA) was added 
followed by further sonication for 3 minutes under similar conditions. This procedure 
resulted in S/O/W nanoemulsion. The nanoemulsion was kept on a shaker bath at room 
temperature for 15-20 minutes followed by complete evaporation of methylene chloride 
under Rotavap for about 2 hrs. Later, this nanodispersion was centrifuged for 50 minutes at 
22,000g. Nanoparticles formed were washed two times with DI water to remove surface 
bound VVD and PVA followed by freeze drying.  
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Characterization of Nanoparticles: 
Entrapment efficiency of nanoparticle  
An aliquot (0.5 mL) of freshly prepared nanosuspension was dissolved in 10 mL of 
DMSO:ACN (20/80; v/v). Later, this solution was thoroughly mixed for 4 hrs and sonicated 
in a bath sonicator to obtain a clear solution. The solution was subjected to centrifugation for 
10 minutes and the supernatant was collected and subsequently analyzed by HPLC to 
estimate VVD entrapment in nanoparticles.  
 
Particle size and zeta potential measurement  
The mean particle size and polydispersity of the nanoparticles were measured at 25°C 
by DLS (Brookhaven Inst. Co., USA) at an operating angle of 90°. A dilute sample of the 
nanosuspension (1:5) in DI water was employed for particle size analysis. At least triplicate 
measurements of each bathes were carried out. For zeta potential measurement, freeze dried 
nanoparticles were suspended in DI water and then surface charge of nanoparticles was 
measured with the Malvern Zetasizer apparatus (Malvern Instruments Ltd, UK).  
 
X ray diffraction (XRD) 
X ray diffraction patterns in this study were obtained by a Rigaku MiniFlex 
automated diffractometer using Cu Kα radiation (1.5405 Å) with a NiKb filter. The tube was 
operated at 30 kV, 15 mA and the scan range was 10–50° 2θ at 0.5˚/min.  Aliquots of sample 
(7.1 mg) were dispersed in benzene on a zero-background silicon plate, air-dried and 
scanned.  
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Scanning electron microscopy (SEM) 
Scanning electron microscopy images were obtained to study the morphology of 
nanoparticles. A drop of nanosuspension was placed on a nucleopore filter in a hand-pumped 
vacuum chamber with a permeable membrane supporting the filter. Vacuum was applied to 
enhance filtration rate.  The filters were mounted on SEM stubs with double-sticky carbon 
tabs and then the edges were coated with colloidal silver for conductivity.  The samples were 
then sputter-coated with platinum for 1 min at 20 mA current.  Images were taken on a 
Hitachi S4700 field-emission SEM at accelerating voltages of 5 and 10 KV. 
 
Transmission electron microscopy (TEM)  
The surface morphology and appearance of nanoparticles were further studied with 
TEM. Briefly, freeze dried sample of nanoparticles was placed on 200-mesh copper carbon-
coated grids and stained with 1.3% phosphotungstic acid. Images were captured on a JEOL 
JEM 1400 transmission electron microscope with a 2k x 2k Gatan digital camera. 
 
Release of the VVD from nanoparticles 
For release study, 1.5 mL of the nanoparticle suspension was added into dialysis bags 
(MWCO:10,000). The dialysis bags were carefully placed into glass tubes containing 9 mL 
of PBS buffer and distilled deionized water. These tubes were stirred at 60 rpm at 37˚C. 
Samples were taken at predetermined time points and the entire release medium was replaced 
by either fresh PBS buffer or distilled deionized water. VVD release from nanoparticles was 
analyzed with HPLC.   
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Results and Discussion: 
The main objective of this study was to formulate and characterize a nanoparticulate 
formulation of a hydrophilic water soluble prodrug of dexamethasone. We have synthesized, 
characterized and established a HPLC method to analyze VVD and dexamethasone in our 
laboratory. The objective of synthesizing dipeptide prodrug of dexamethasone was to target 
peptide transporters present on basolateral surface of RPE following subconjunctival 
injection. Aqueous solubility of VVD was found to be almost 50-fold higher than the parent 
drug. This solubility enhancement was very crucial to overcome several limitations 
associated with the current delivery of dexamethasone. However, at the same time, 
development of a nanoparticulate formulation with higher loading efficiency became a 
challenging task. Conventional methods of nanoparticles preparation such as O/W and 
W/O/W emulsion failed to provide higher VVD entrapment efficiency (entrapment less than 
10 %) (unpublished data). Higher affinity of VVD for the external aqueous phase was the 
primary reason for its lower entrapment when the conventional methods of preparation were 
employed. Due to higher aqueous solubility, VVD molecules diffuse readily into the external 
aqueous phase resulting in lower partitioning into the hydrophobic polymeric matrices. 
Several investigators have chemically modified the hydrophilic drug molecules to 
hydrophobic molecules to enhance its partitioning into nanoparticles. However, it is a tedious 
and cumbersome process. Moreover, these modifications might result in the loss of 
bioactivity of the parent molecule. Hence, there is a strong need to design an alternative 
strategy to convert these water soluble compounds into water insoluble lipophilic moieties 
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because these water insoluble compounds can be easily encapsulated in polymeric 
nanoparticles.  
Structures of VVD and dextran sulphate are shown in Figure 14. We used dextran 
sulphate as a complexing agent for VVD. Dextran is a polymer of anhydroglucose and it has 
been widely employed as a potential adjuvant in various pharmaceutical formulations [135-
140]. Dextran sulphate contains 2.3 sulphate groups per glucosyl residue [138, 139]. In the 
current study, terminal amino group of VVD was complexed with the sulphate group of 
dextran sulphate to form water insoluble HIP complex. HIP complex of VVD was 
hydrophobic in nature and its solubility was dramatically reduced in water and organic 
solvents such as methylene chloride and acetonitrile. This complex form of VVD was 
encapsulated to prepare a nanoparticulate based formulation. Therefore, in the current study, 
S/O/W emulsion method was employed to formulate nanoparticles.  
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Figure 14:  Structures of valine-valine-dexamethasone (A) and dextran sulphate (B) 
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HIP complex formation was studied at different molar ratios of dextran sulphate to 
VVD such as 0.003, 0.007, 0.014, 0.029 and 0.058. These molar ratios represent different 
amounts of dextran sulphate added to the VVD solution to form the HIP complex. A 
stoichiometric relationship between the amounts of dextran sulphate added and the formation 
of HIP complex was obtained (Figure 15). This result was consistent with previously 
published studies of HIP complexes of leuprolide, insulin, melittin which were prepared 
using surfactants [93, 99]. When the molar ratio of dextran sulphate to VVD was 0.014, more 
than 99% of VVD was found in the HIP complex form (Figure 15).  
 
Figure 15: Effect of molar ratio of dextran sulphate/valine-valine-dexamethasone on HIP 
complexation 
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Theoretically, at this molar ratio, negatively charged species (sulphate groups of 
dextran sulphate) and positively charged species (amino groups of VVD) were at equal 
concentration in the solution. Almost all VVD molecules were ionically complexed with 
dextran sulphate. When the molar ratio was less than 0.014, sulphate groups present in the 
aqueous solution were not sufficient to completely bind to all the available amino groups of 
VVD. Therefore, after HIP complex formation, uncomplexed VVD was also observed in the 
supernatant. When the molar ratios of dextran sulphate to VVD were 0.003 and 0.007, 45% 
and 70% of VVD molecules were available in the HIP complex form. Theoretically, at these 
molar ratios, the sulphate groups present in the solution were sufficient to complex only 25% 
and 50% of the amino groups of VVD molecules. Still, almost 45% and 70% of VVD 
molecules were complexed with dextran sulphate (Figure 15). Therefore, two different 
mechanisms may be responsible for HIP complex formation (1) ion pairing and (2) 
hydrophobic interactions. After mixing aqueous solutions of dextran sulphate and VVD, 
apart from ion pairing, hydrophobic interactions can rightfully contribute to complex 
formation. Due to hydrophobic interactions, even at lower molar ratios (0.003 and 0.007), 
significant binding of dextran sulphate with VVD was observed as reported by several 
investigators [98]. Binding efficiency was more than 99% at any molar ratio higher than 
0.014. Moreover, an excess addition of dextran sulphate did not result in any significant 
change in the HIP complexation with VVD. This was quite surprising. It is probable that 
mechanism of HIP complex formation using dextran sulphate differs than that of HIP 
complex formation with any surfactant. In the later mechanism, excessive addition of 
surfactant beyond its critical micelle formation concentration (CMC) will cause formation of 
micelles. Due to micellization, reversion of HIP complexation occurs and thus, solute 
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molecules solubilize again [99]. Interestingly, in case of dextran sulphate, similar behavior 
even at higher molar ratio of dextran sulphate to VVD (any molar ratio greater than 0.014) 
was not observed. This may be because of predominance of nonspecific hydrophobic 
interactions between dextran sulphate and VVD, which prevented the formation of micelles. 
Further studies are in progress to investigate this mechanism where we have employed small 
molecular weight of dextran sulphate and anionic surfactants to form HIP complex. 
The effect of pH on complexation of VVD with dextran sulphate was also studied. 
Previously, we have investigated the buffer stability of the prodrugs at different pH values 
(Refer table 8 for details). Our results suggested that stability of VVD was higher at lower 
pH and as pH was increased, the stability of prodrug was found to be decreased. This 
stability data was also consistent with the previously published results from our laboratory 
[40]. The result of this experiment further explains the role of hydrophobic interactions. 
Amino group of VVD has pKa value close to ≈10. Thus, at pH 4.5, 5.5, 6.5, 7.5 and 8.5, 
amino group would have net positive charge and hence can bind with sulphate group of 
dextran sulphate. As pH of aqueous solution of VVD approaches towards its pKa (from pH 
4.5 to pH 8.5), less amino group of VVD would carry cationic property. Hence, less 
molecules of VVD will ionically bind with dextran sulphate and more VVD will remain in 
the supernatant. However, more than 80% of VVD in the form of HIP complex was found at 
pH 6.5, 7.5 and 8.5 (Figure 16). A steep decline in the percentage binding of VVD molecules 
with dextran sulphate was not observed. This phenomenon can be attributed to the 
hydrophobic interactions. As the pH of the VVD solution approached its pKa, hydrophobic 
interactions became more predominant than the ionic interactions. Similar behavior was also 
reported by other investigators in the past [98].  
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Figure 16: Effect of pH on valine-valine-dexamethasone HIP complex formation with 
dextran sulphate 
81 
 
     The dissociation of VVD from HIP complex was also studied. Since interaction between 
dextran sulphate and VVD was mainly driven by non-covalent forces such as ionic and 
hydrophobic interactions, dissociation of VVD from HIP complex in the presence of 
negatively charged species was probable. HIP complex (prepared at molar ratio of dextran 
sulphate/VVD 0.014) was redispersed in DPBS with varying concentrations of NaCl (10 and 
100mM) and distilled deionized water. Analysis of supernatant revealed that almost 5 and 15 
% VVD dissociated from the HIP complex which were redispersed with DPBS buffer having 
10 and 100mM of NaCl, respectively (Figure 17). Interestingly, we did not observe 
significant dissociation of VVD from HIP complex which was redispersed with DDW 
(Figure 17). This might be because of absence of negatively charged species such as chloride 
ions in DDW, and thus VVD did not dissociate from the HIP complex. Slow dissociation of 
VVD from the HIP complex can be beneficial in several ways. Due to slow dissociation, 
release of VVD can be sustained at the target site. Therefore, selection of the complexing 
agent is very important in the HIP complexation process. Dissociation and release parameters 
of a drug molecule may vary depending upon the nature of the complexing agent. 
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Figure 17: Effect of dispersing medium on the dissociation of valine-valine-dexamethasone 
from HIP complex 
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Nanoparticles were prepared with S/O/W emulsion method. Recently, this method 
was investigated for the preparation of nanoparticles for a variety of drug molecules [91, 
141]. Methylene chloride was selected as a common solvent to dissolve PLGA 85:15 and 
disperse HIP complex. Critical parameters affecting nanoparticle formulation were total 
volume of methylene chloride used, total duration of vortex processing and the duration of 
sonication. A fine dispersion of solid (HIP complex of VVD with dextran sulphate) in oil 
(methylene chloride) was necessary to prepare final S/O/W emulsion. Addition of PLGA 
aided in rapid dispersion of HIP complex in methylene chloride. As the amount of PLGA 
85:15 increased, the dispersion process of HIP complex in methylene chloride became rapid. 
Sonication was carried out to achieve a fine dispersion of solid (HIP complex) in oil 
(methylene chloride). To this S/O dispersion, 30 mL of 1% PVA solution was added 
followed by sonication in ice bath to obtain S/O/W nanoemulsion. Temperature was 
controlled during the sonication process using ice bath to ensure stability of the VVD.  Later, 
methylene chloride was evaporated with a rotavap and nanoparticles were freeze dried and 
stored at -80°C. 
Prepared nanoparticles were characterized with respect to size, zeta potential and 
surface morphology. Size and shape of the colloidal dosage form dramatically affects in vivo 
performance. The size of the nanoparticles was found to be less than 200 nm in all cases. 
Low polydispersity values indicate uniformity of the particle size and the narrow particle size 
distribution for various batches of nanoparticles. Based on results of the present study, we 
hypothesized rapid endocytosis and translocation of these nanoparticles in the retinal cells. 
Previous studies from other labs have also shown endocytosis of nanoparticles by retinal 
cells [133, 134]. Our result also shows feasibility of preparing nanoparticles with 
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uniform size and narrow particle size distribution using the S/O/W emulsion method. For all 
batches of nanoparticles, zeta potential values were negative (Table 11). This could be due to 
negative surface charges of PLGA. These results are consistent with previously published 
studies which have shown the presence of a negative surface charge on the PLGA 
nanoparticles [138, 139, 142]. 
 
Table 11: Zeta potential, particle size, polydispersity and entrapment efficiency of various 
batches of nanoparticles  
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Surface morphology of nanoparticles was characterized with SEM and TEM (Figure 
18 and 19). These studies revealed that particles were uniform in appearance and round in 
shape. This result further confirmed particle size analysis data by DLS. Nanoparticles 
appeared uniform and did not exhibit significant aggregation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Scanning electron microscope images of nanoparticles prepared with different 
ratios of HIP complex: PLGA.  (A) 1:10 (B) 1:15 and (C) 1:20 
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Figure 19: Transmission electron microscopic images of nanoparticles prepared with 
different ratios of HIP complex: PLGA. (A) 1:10 (B) 1:15 and (C) 1:20
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     An important objective of this study was to achieve higher entrapment efficiency of VVD 
in polymeric nanoparticles. PLGA 85:15 was selected in the current study due to its higher 
lactide content. As the lactide content increases, hydrophobic interactions with HIP complex 
would increase as well. This might result in higher partition of HIP complex in polymeric 
matrix of PLGA. Results clearly show that when higher amounts of PLGA 85:15 were added 
for the nanoparticle preparation, entrapment of VVD in nanoparticles increased 
simultaneously. Among the three different ratios of VVD in HIP complex form: PLGA 
studied, the least entrapment (≈25 %) was observed when the ratio was 1:10. Maximum 
entrapment of VVD (≈45 %) was obtained when the ratio reached 1:20 (Table 12).  Dramatic 
enhancement in the entrapment efficiency was noticed with the HIP complex technique 
relative to conventional methods of preparation such as single and double emulsion. This 
study also shows that other than protein based therapeutics; HIP complexation can also be a 
useful tool to enhance the loading of small hydrophilic, water soluble molecules in 
nanoparticles. This technique would provide the flexibility to alter the aqueous solubility of a 
compound in a reversible manner. Therefore, it may serve as a viable alternative to covalent 
modification of drug molecules. Selection of complexing agent is very crucial because 
physicochemical properties of HIP complex may vary depending on the nature of the 
complexing agent. 
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VVD was amorphous in nature which was also one of the reasons for its higher 
aqueous solubility. Therefore, XRD studies were carried out to understand if the VVD still 
remained in the amorphous form within the core of nanoparticles. XRD diffractogram 
showed lack of crystalline nature for VVD, dextran sulphate, HIP complex and PLGA 
(Figure 20). XRD diffractogram of the freeze dried nanoparticles of different batches is also 
shown in the same Figure, which confirms that VVD exists in the amorphous form within 
nanoparticles matrix. 
Figure 20 : X-ray diffractogram of valine-valine-dexamethasone, dextran sulphate, HIP 
complex, PLGA, in different batches of nanoparticles 
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Finally, the release of VVD from nanoparticles was compared into two different 
releasing medium. PBS buffer and DDW were selected as release medium. Based on 
previous result of dissociation of VVD from HIP complex, it is likely that slower release of 
VVD from the nanoparticles will occur in the presence of DDW relative to PBS buffer. Our 
results show dramatic difference in the release of VVD in two different mediums. In case of 
PBS buffer, significant burst effect was observed which resulted in release of ≈ 80 % of 
VVD in 24 hrs. This could be due to rapid dissociation of VVD from HIP complex which 
was absorbed on surface and also entrapped within polymeric matrix. The burst release 
phenomenon from PLGA nanoparticles has been widely reported in the literature [143, 144]. 
However, in case of DDW, burst effect was significantly attenuated (Figure 21). This may be 
due to the absence of negatively charged ions in DDW which resulted in the slow 
dissociation of VVD from HIP complex. Moreover, due to higher molecular weight, 
diffusion of HIP complex from polymeric matrix would be slower compared to free VVD. 
Overall release was also comparatively slower when DDW was chosen as the releasing 
medium. Release of VVD was sustained for 14 days in DDW compared to 5 days where PBS 
served as the medium (Figure 21). Release data also suggest that nanoparticles may sustain 
the release of VVD at the targeted site. Further studies are in progress to evaluate in vivo 
performance of a novel sustained release VVD nanoparticulate formulation in the rabbit 
animal model. Effect of ionic strength of media and osmotic pressure on release of VVD 
from nanoparticles is under investigation. In future, we also intend to study and calculate 
diffusion and dissociation rate constant for HIP complex.    
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Figure 21: Comparison of in vitro release of the valine-valine-dexamethasone from 
nanoparticles in different releasing media 
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Conclusion  
 
The objective of this study was to design and characterize a nanoparticulate based 
sustained release formulation of a water soluble prodrug of dexamethasone. A hydrophobic 
ion pairing (HIP) complexation method with dextran sulphate as a complexing agent was 
utilized to convert hydrophilic prodrug into a hydrophobic complex. Various parameters of 
HIP complexation were studied and optimized. HIP complex of VVD was encapsulated in 
nanoparticles by S/O/W emulsion method. Prepared nanoparticles were characterized with 
respect to size, zeta potential and surface morphology (using SEM and TEM). Entrapment 
efficiency of prodrug was dramatically enhanced compared to conventional techniques such 
as single and double emulsion methods. X-ray diffraction studies revealed the amorphous 
nature of the prodrug within nanoparticles. A significant difference in the release profile of 
VVD was observed from nanoparticles when we employed PBS buffer and DDW as 
releasing medium. Finally, a simple yet novel method was developed to encapsulate water 
soluble hydrophilic molecules in polymeric nanoparticles. This method can also be 
applicable to other small hydrophilic and peptide/protein based molecules.  
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART IIA: DESIGN AND EVALUATION OF A NOVEL NANOPARTICULATE BASED 
FORMULATION CONTAINING A HIP COMPLEX FORM OF AN ENZYME: A CASE 
STUDY INVOLVING LYSOZYME PART IIB: ENCAPSULATION OF PROTEIN-
POLYSACCHARIDE HIP COMPLEX IN POLYMERIC NANOPARTICLES 
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CHAPTER 5 
INTRODUCTION 
Overview 
Protein based therapeutics such as antibodies, blood products and vaccines have 
gained wide acceptance in the past decade to treat a variety of disorders. Development of a 
nanoparticulate based dosage form of these molecules is still considered as a major challenge 
by scientists in the drug delivery field. Single emulsion method (O/W) and double emulsion 
method (W/O/W) are the most widely used conventional methods to prepare nanoparticles. 
However, these methods employ sonication and organic solvents to prepare nanoparticles. 
Protein based therapeutics have shown rapid denaturation and conformational change due to 
sonication and exposure to organic solvents. Protein based molecules may aggregate and 
eventually lose their biological activity due to physical and chemical stresses observed during 
formulation development e.g., exposure to organic solvents and sonication. These molecules 
may also denature or lose their biological activity during storage and lyophilization. 
Sonication is employed to ensure homogeneous dispersion of an emulsion. However, 
sonication may result in large pressure and temperature gradient which cause denaturation 
and aggregation of protein molecules. Moreover, sonication also causes generation of high 
shear force and free radicals which cause protein denaturation. Organic solvents 
preferentially interact with the non-polar amino acids of the protein via hydrophobic 
interactions. Normally, these non-polar amino acids are present in the core of the protein 
structure. Hence, in presence of organic solvents, the native structure and conformation of 
protein are usually altered. This might result in loss of biological activity of a protein 
molecule. Another crucial formulation related limitation of protein molecules is their 
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hydrophilicity. Due to hydrophilic nature of these molecules, they often partition poorly in 
the polymeric matrix during encapsulation resulting in minimal loading in nanoparticles. Due 
to poor loading of these molecules, a higher amount of polymer is needed to develop a 
formulation.  
Hydrophobic ion pairing (HIP) complexation approach has gained wide acceptance in 
the delivery of peptide and protein based therapeutics. In this approach, ionizable functional 
groups of a drug molecule are ionically complexed with the surfactant or a polymer having 
oppositely charged functional groups. The resulting drug-polymer or drug-surfactant 
complex is known as HIP complex. Since the hydrophilic drug molecule exists in the form of 
a complex which is hydrophobic, its partition in the polymeric matrix can be significantly 
enhanced during encapsulation. Protein and polymer (used for HIP complexation) primarily 
interact due to ionic interactions during formation of HIP complex. Hence, the complex can 
be dissociated in presence of excess of the oppositely charged ions. Further, HIP 
complexation would obviate the use of any covalent modification in protein molecules to 
make them more hydrophobic in nature. These covalent modifications may also result in the 
irreversible loss in the biological activity of these molecules. Various studies have been 
performed in the past to understand the nature of protein-surfactant interaction. HIP 
complexation approach has been studied with various peptide and protein based molecules 
such as leuprolide, insulin, mellitin, lysozyme, etc. HIP complexation of protein based 
therapeutics has resulted in overcoming various issues associated with delivery of protein 
molecules such as bioavailability and stability. Moreover, HIP complexation has also shown 
to impart conformational stability to protein molecules.    
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This part of dissertation deals with HIP complex formation of protein molecules 
(lysozyme and bovine serum albumin (BSA)) with a polysaccharide molecule (dextran 
sulphate). Basic amino acids of these proteins can be ionically complexed with sulphate 
group of dextran sulphate and the resulted HIP complex can be entrapped in polymeric 
matrix of nanoparticles.  
Statement of the Problem 
Conventional methods of nanoparticle preparation such as single emulsion (O/W) and 
double emulsion (W/O/W) have failed to provide higher encapsulation of protein molecules 
in nanoparticle matrix. This is mainly due to rapid leaching of these hydrophilic molecules in 
external aqueous phase during preparation. HIP complexation of protein molecules has been 
investigated as an alternative to enhance loading of these molecules in nanoparticles. Protein 
molecules contain a complex secondary and tertiary structure stabilized by various covalent 
and non-covalent forces. Non-covalent forces include electrostatic interactions, hydrogen 
bonds, hydrophobic interactions and Van der Waals interactions. During HIP complex 
formation, protein molecule precipitates in complex form with dextran sulphate (DS). Due to 
precipitation, they may undergo conformational changes or partial unfolding. One may also 
argue irreversible aggregation of protein molecule during the precipitation of HIP complex 
which would not be biologically active. Apart from that, aggregated form of a protein 
molecule may also generate an immune response after administration. Hence, it is very 
important to characterize the forces involved in the formation of a HIP complex and 
distinguish HIP complex formation process with aggregation. Due to large size, presence of 
various functional groups and glucosyl ring structure, DS may interact extensively with the 
protein molecule via electrostatic interactions, hydrogen bonds, hydrophobic interactions and 
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Van der Waals interactions. Since, the similar forces also play a crucial role in stabilizing the 
protein molecule, it would be important to understand the effect of HIP complexation on 
stability of the complexed protein. It is challenging to achieve higher loading of protein 
molecules in nanoparticles without affecting its structure (secondary and tertiary structure) 
and biological activity. Further, it is essential to study the effect of encapsulation process 
parameters on the structure/activity of the protein molecule.  
Objectives 
The objectives of this part of dissertation project are: 
(a) to prepare and characterize hydrophobic ion pairing (HIP) complexes of two model 
protein molecules (Lysozyme and BSA) with dextran sulphate as a complexing agent 
(b) to characterize nature of interaction between protein molecules and complexing agent 
(dextran sulphate) 
(c) to study the effect of HIP complexation on structure (secondary and tertiary) and 
activity of protein molecules 
(d) to prepare nanoparticles of protein molecules using PLGA as a matrix forming 
polymer 
(e) to characterize nanoparticles with respect to size, surface morphology, entrapment 
efficiency and release profile 
(f) to study the structure (secondary and tertiary) and activity of protein molecules after 
releasing from nanoparticles 
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CHAPTER 6 
DESIGN AND EVALUATION OF A NOVEL NANOPARTICULATE BASED 
FORMULATION CONTAINING A HIP COMPLEX FORM OF AN ENZYME:  A CASE 
STUDY INVOLVING LYSOZYME 
Rationale 
Delivery of protein based therapeutics has become a challenge for the scientists in the 
drug delivery field. Colloidal dosage forms of small peptide and protein based molecules 
have been widely investigated to overcome absorption and stability related issues of these 
molecules [145, 146]. However, success of this approach is mainly dependent on 
understanding of the formulation parameters. Conventional methods of nanoparticle 
preparation such as single and double emulsion have often failed to provide higher 
entrapment of peptide and protein molecules in polymeric matrix [145]. Low entrapment is 
attributed to leaching of these hydrophilic molecules into external aqueous phase during the 
encapsulation process. These hydrophilic molecules have higher affinity for external aqueous 
phase compared to hydrophobic polymeric matrix. Use of organic solvents and physical 
stress during homogenization often cause denaturation and irreversible aggregation of these 
molecules resulting in loss of their biological activity [147, 148]. Other major challenges to 
develop a nanoparticulate based formulation of protein molecules include significant burst 
release and loss of biological activity after encapsulation within the polymeric matrix.  Poly- 
lactic-co-glycolic acid (PLGA) is one of the most widely employed biocompatible and 
biodegradable polymers to prepare nanoparticles. However, this polymer has shown a 
detrimental effect on stability of the entrapped protein molecules [149-151].  
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Hydrophobic ion pairing (HIP) complexation is a technique to stoichiometrically 
complex ionizable functional groups of protein and peptide molecules with oppositely 
charged functional groups of surfactant molecules [96]. Hydrophilic and water soluble 
protein molecules can be converted into hydrophobic form by complexing them with a 
surfactant molecule. Since hydrophilic drug molecules exist in hydrophobic form in the HIP 
complex; their entrapment efficiency can be significantly enhanced in nanoparticles during 
the encapsulation process [79, 93, 94, 102]. HIP complexation also offers several advantages 
such as enhancement of conformational stability to protein molecules and increase in their 
bioavailability along with substantial improvement in their loading in nanocarriers [93, 94, 
96-98, 102]. Various peptide and protein based therapeutic agents were converted in their 
HIP complexes using surfactant molecules and these complexes were found to overcome 
many of the above mentioned problems associated with their delivery.   
In the present study, we have investigated the HIP complex phenomenon of a model 
basic protein, lysozyme with dextran sulphate (DS) as a complexing agent. Lysozyme is an 
enzyme composed of 129 amino acids while dextran sulphate is a polysaccharide (a polymer 
of anhydroglucose) [135, 138]. Basic amino acids of lysozyme can be ionically complexed 
with sulphate group of DS and the resulted HIP complex can be entrapped in polymeric 
matrix. HIP complex of lysozyme with surfactant (sodium oleate) was studied in the past by 
Yoo et al [98]. These investigators have characterized HIP complex along with preparation of 
nanoparticles. In the present work, we have employed DS (molecular weight 9000-20000 Da) 
as a complexing agent. DS has been previously employed as a potential adjuvant in various 
pharmaceutical formulations [135, 138]. 
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Macromolecules contain a complex secondary and tertiary structure stabilized by 
various covalent and non-covalent forces. Non-covalent forces include electrostatic 
interactions, hydrogen bonds, hydrophobic interactions and Van der Waals interactions [89, 
152, 153]. During HIP complex formation, lysozyme precipitates in complex form with DS. 
Due to precipitation, lysozyme may undergo conformational changes or partial unfolding. 
One may also argue irreversible aggregation of lysozyme during the precipitation of HIP 
complex which would not be enzymatically active. Apart from that, aggregated form of a 
protein molecule may also generate an immune response after administration [154]. Hence, it 
is very important to characterize the forces involved in the formation of a HIP complex and 
distinguish HIP complex formation process with aggregation. Due to large size, presence of 
various functional groups and glucosyl ring structure, DS may interact extensively with the 
protein molecule via electrostatic interactions, hydrogen bonds, hydrophobic interactions and 
Van der Waals interactions [85,157]. Since, the similar forces also play a crucial role in 
stabilizing the protein molecule, it would be important to understand the effect of HIP 
complexation on stability of the complexed protein. Contribution from each force during a 
HIP complex formation would depend on nature of the protein molecule, size and structure 
of the complexing agent, ionic strength of the medium and pH of the aqueous solutions of 
complexing agent and protein. We have also investigated effect of complexing agent (DS) on 
physicochemical properties (solubility and dissociation of protein from HIP complex) of HIP 
complex. 
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In the present study, we also intended to characterize the electrostatic interactions of 
amino groups of lysozyme with the sulphate groups of DS using Fourier transform 
spectroscopy (FTIR). Moreover, it was also important to understand how lysozyme molecule 
would dissociate from the HIP complex and regains its native structure because only the 
native form of lysozyme would have enzymatic activity. Regeneration of lysozyme in its 
native form would also eliminate the possibility of its irreversible aggregation during 
formation of HIP complex. Hence, we also studied enzymatic activity of lysozyme after 
dissociation from HIP complex and compared it with the enzymatic activity of freshly 
prepared solution of lysozyme. 
Further, we prepared nanoparticles using spontaneous emulsion solvent diffusion 
method as published earlier by Yoo et al [98] . There were several major reasons to select 
this method over other methods to prepare nanoparticles. Conventional methods of 
nanoparticle preparation (single and double emulsion methods) involve sonication of 
lysozyme in presence of organic solvents which inactivates the enzyme [155]. Apart from 
that, some investigators have also reported precipitation of enzymatically inactive form of 
lysozyme in presence of methylene chloride [155]. Spontaneous emulsion solvent diffusion 
method does not employ any kind of sonication or treatment with organic solvent [98]. 
Instead dimethyl sulfoxide (DMSO), a highly protein compatible solvent is employed as a 
common solvent to solubilize polymer and HIP complex form of lysozyme. Doelkar et al. 
have studied the effect of various solvents, non-solvents, polymers and surfactants on the 
preparation of nanoparticles using spontaneous emulsion solvent diffusion method [91]. We 
also characterized the prepared nanoparticles with respect to particle size and surface 
morphology using scanning electron microscopy (SEM). Moreover effect of different ratios 
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of PLGA polymer on entrapment of lysozyme was studied. Further, we have performed X-
ray diffraction (XRD) analysis to investigate the effect of HIP complexation and 
nanoparticles preparation on crystal structure of lysozyme. Finally, release of lysozyme from 
PLGA nanoparticles was also studied and enzymatic activity of the released lysozyme was 
compared with freshly prepared solution of lysozyme.  
Materials and method: 
Materials: Lysozyme, dextran sulfate sodium salt (molecular weight 9000-20000 Da), Poly 
(DL-lactide-co-glycolide) (PLGA 85:15, molecular weight of 50,000-75,000 Da), 
bicinchoninic acid (BCA), copper sulphate and lyophilized cells of Micrococcus 
lysodeikticus were purchased from sigma Aldrich. DMSO and micro BCA protein assay kit 
were purchased from thermo scientific. All the solvents and other reagents of analytical grade 
were purchased from local supplier and used as such without further purification. Double 
distilled water (DDW) was used throughout the entire study.  
 
Effect of different molar ratios of DS to lysozyme on HIP complex formation   
Stock solutions of DS and lysozyme were prepared in DDW and Tris buffer pH 9, 
respectively. Lysozyme is a globular protein which contains various basic amino acids 
(lysines and arginines) on its surface. Previous study by Yoo et al. has shown HIP 
complexation of lysozyme using lysine amino acids [98]. DS contains 2.3 sulphate groups 
per glucosyl residue. Once both the aqueous solutions were mixed and vortexed, HIP 
complex formed instantaneously. HIP complexes were prepared in the following molar ratios 
of DS/lysozyme such as 0.023, 0.045, 0.068, 0.09, 0.18 and 0.36. These molar ratios 
represent the addition of different amounts of DS into earlier prepared lysozyme solution 
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(5mg/mL). Once formed, the solution was vigorously vortexed for 3 minutes followed by 
centrifugation at 10000 RPM for 10 minutes to separate HIP complex from supernatant. 
Uncomplexed lysozyme was estimated in the supernatant using BCA assay. Percentage 
complexation of lysozyme with DS was calculated using the following equation. 
% complexed lysozyme = [(Initial amount of lysozyme – amount of lysozyme in 
supernatant)/ Initial amount of lysozyme)] *100    (Eq. 2.) 
 
Dissociation of HIP complex of lysozyme and DS  
Dissociation of lysozyme from HIP complex was studied to characterize the nature of 
interactions between lysozyme and DS. Initially, HIP complexes of lysozyme and DS were 
prepared at the molar ratio of 0.09 followed by measurement of uncomplexed lysozyme in 
supernatant. To these complexes, DPBS buffer having different concentrations of NaCl (10 
mM, 50 mM, 100 mM, 200 mM, 400 mM and 750 mM) was added  and HIP complexes were 
redispersed. Similarly, we also redispersed HIP complex in the presence of Dulbecco's 
Phosphate Buffered Saline (DPBS) and DDW for comparison. After 12 h of equilibration, 
samples were centrifuged and dissociated lysozyme was estimated in the supernatant with 
BCA assay.  
 
FTIR study: 
FTIR analysis was carried out with an infrared spectrophotometer (Perkin-Elmer, 
Waltman, MA). Samples (lysozyme, DS and HIP complex) were brought into intimate 
contact with the diamond crystal by applying a loading pressure. The samples were casted on 
diamond crystal top-plate of Attenuated Total Reflectance (ATR) accessory and scanned 
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between 650 – 1800 cm-1. Spectra obtained using this device represents the average of 32 
individual scan possessing a spectral resolution of 4 cm
-1
. 
 
Evaluation of enzymatic activity of lysozyme after dissociation from HIP complex 
Initially, HIP complex of lysozyme with DS was prepared as per earlier mentioned 
protocol. Later, this complex was incubated with 1mL of PBS buffer (66 mM and pH 6.2) for 
12 hrs. This resulted in dissociation of the HIP complex. This solution was further subjected 
to centrifugation and protein estimation was carried out for supernatant. Enzymatic activity 
of lysozyme in supernatant was measured and compared with freshly prepared lysozyme 
solutions in the concentration range of 50, 75, 100, 150, 200 and 250 µg/mL. Enzymatic 
activity of lysozyme was studied by following the earlier published protocol [156]. Briefly, 
M. luteus (lysodeikticus) suspension was prepared in the concentration of 0.24 mg/mL in 
PBS buffer (66 mM) at pH 6.2. 50 µl of sample or standard prepared in above mentioned 
concentration was added in 2.5 mL of M. luteus suspension followed by incubation for 3 
minutes. Activity of lysozyme was determined by measuring the decrease in optical density 
of a M. luteus suspension at 450 nm. This study was carried out in triplicate at room 
temperature.  
 
Preparation of nanoparticles: 
Nanoparticles were prepared using PLGA 85:15 as a polymer. Nanoparticles were 
prepared by spontaneous emulsion solvent diffusion method published earlier by Yoo et al 
with minor modifications [98]. Briefly, 5 mg of lysozyme present in HIP complex form with 
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DS and PLGA 85:15 were dissolved in total of 3 mL of DMSO. This solution was added 
drop wise using a syringe into 25 mL of 1% poloxamer solution under constant stirring. 
Nanoparticles were formed instantaneously as both the solutions were mixed. 
Prepared nanoparticles were stirred for 1 hr followed by centrifugation. Further, 
nanoparticles were washed 2 times with DDW to remove surface bound lysozyme, 
poloxamer and DMSO. Various batches of nanoparticles were prepared using different ratios 
of lysozyme in HIP complex to PLGA 85:15(1:5, 1:10 and 1:15). This study was carried out 
in triplicate. Blank nanoparticles were also prepared by employing only polymer in similar 
amounts.   
Characterization of Nanoparticles 
Entrapment efficiency of nanoparticles 
For entrapment efficiency, 10 mL of DMSO was added into earlier prepared 
nanoparticles and particles were dissolved completely. Standard solution of lysozyme was 
prepared in DMSO. Entrapment was calculated based on the absorbance measured at 280nm 
using UV spectrophotometer. This absorbance was corrected for the absorbance of blank 
nanoparticles prepared using PLGA. This study was carried out in triplicate.  
 
Particle size measurement  
The mean particle size and polydispersity of the nanoparticles was measured by DLS 
(Brookhaven Inst. Co., USA) at an operating angle of 90° and at a temperature of 25 °C. A 
dilute sample of the nanosuspension was taken for particle size analysis and at least three 
measurements of each batch were carried out.  
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Scanning electron microscopy (SEM) 
Scanning electron microscopy images were obtained to study morphology of 
nanoparticles. A drop of nanosuspension was placed on a nucleopore filter in a hand-pumped 
vacuum chamber with a permeable membrane supporting the filter. Vacuum was applied to 
enhance filtration rate.  The filters were mounted on SEM stubs with double-sticky carbon 
tabs and then the edges were coated with colloidal silver for conductivity.  The samples were 
then sputter-coated with platinum for 1 min at 20 mA current.  Images were taken on a 
Hitachi S4700 field-emission SEM at accelerating voltages of 5 and 10 KV. 
 
X ray diffraction (XRD)  
X-ray diffraction patterns in this study were obtained by using a Rigaku MiniFlex 
automated diffractometer using Cu Kα radiation (1.5405Å) with a Ni Kb filter. The tube was 
operated at 30 kV, 15 mA and the scan range was 10–50° 2θ at 0.5˚/min.  7.1-mg sample 
aliquots were dispersed on a zero-background silicon plate, air-dried and scanned.  
 
Release of the lysozyme from nanoparticles and its enzymatic activity  
For release study, 1 mL of the nanoparticle suspension (ratio 1:5) in PBS buffer was 
filled into an Eppendorf tube. These tubes were stirred at 60 rpm at 37˚C. At predetermined 
time points, samples were subjected to centrifugation and the supernatant was collected. 
Nanoparticles were again re-suspended with 1mL of PBS buffer (containing 3-5% mannitol) 
and release study was continued. Concentration of lysozyme in the release samples was 
estimated by measuring supernatant using BCA/micro BCA assay. After protein estimation, 
the released samples were subjected for enzymatic activity assay as mentioned in the earlier 
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section. Activity of lysozyme was determined by measuring the decrease in optical density of 
a M. luteus suspension at 450 nm. Standard solutions of lysozyme were also prepared at same 
concentrations and their enzymatic activity was also measured for comparison.  
 
Result and Discussion  
HIP complexation has been widely investigated because of its potential to ionically 
complex charged functional groups of the small molecules, peptides as well as 
macromolecule with oppositely charged surfactant molecules. Basically, HIP complexation 
alters the solubility of a charged molecule and hence loading of the molecule can be 
enhanced in nanoparticles. Other major advantage of HIP complexation includes restricting 
conformational flexibility of the macromolecules and thus these molecules can be stabilized. 
In the present work, we have chosen lysozyme a model enzyme for the study. It is a basic 
protein (129 amino acids) and contains various basic amino acids which can be complexed. 
Currently, most of the literature focuses on use of surfactants to form HIP complex [93, 94, 
98, 102]. In the present work, we have utilized a sulphated polysaccharide, dextran sulphate 
(mol wt 9-20 K Da), to ionically complex amino groups of lysozyme. Being a long chain 
polymer, dextran sulphate interacts extensively with the lysozyme molecule. Various forces 
involve in this interactions include electrostatic interactions, hydrogen bonds, hydrophobic 
interactions and Van der Waals forces [85, 157]. We studied the effect of various molar ratio 
of DS/lysozyme on HIP complex formation. Our result confirms a linear relationship 
between amount of DS added and formation of HIP complex (Figure 22).  
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Figure 22 : Effect of molar ratios of dextran sulphate:lysozyme on HIP complexation 
 
At any molar ratio less than 0.09, amount of DS was not sufficient to complex with 
all the molecules of lysozyme present in the solution. Hence, at molar ratios of 0.023, 0.045 
and 0.068, we observed almost 73%, 48% and 19.5% of uncomplexed lysozyme molecules in 
supernatant, respectively (Figure 22). Interestingly, at molar ratio greater than 0.09 (0.18 and 
0.36), more than 98% of the lysozyme molecules were found in the HIP complex form with 
DS. This result was quite surprising because excess of DS did not result in any significant 
change in the HIP complexation with lysozyme. This result was quite different than 
previously published studies in which the investigators have employed a surfactant to form 
HIP complex of protein molecules [93, 94]. In case of HIP complexation involving a 
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surfactant molecule, investigators have observed the micellization phenomenon at the higher 
concentration of surfactant (beyond critical micellar concentration). Micelle formation results 
in the solubilization of HIP complex and eventually the solution become clear. Our result 
clearly shows the difference in characteristics of HIP complex and it could be because we 
have employed a polymer (DS) to make HIP complex. Moreover, formation of micelles 
require a balance in the hydrophilic and hydrophobic forces which could be absent in the 
present scenario. We have further employed small molecular weight of DS and other anionic 
surfactants to investigate this mechanism in detail. 
We also studied dissociation of lysozyme from HIP complex by redispersing HIP 
complex with DPBS containing different concentrations of NaCl (10mM to 750mM). Since 
ionic interactions play a driving force for the formation of HIP complex, we conceptualized 
that HIP complex would dissociate in the presence of excess of oppositely charged ions (Cl
-
). 
Results of this study are shown in Figure 23 which clearly indicates a linear relationship 
between addition of different concentrations of NaCl and dissociation of lysozyme from HIP 
complex. We observed that as concentration of chloride ion increased, these ions replaced the 
negatively charged sulphate groups resulting in dissociation of HIP complex. Samples of HIP 
complexes which were redispersed with DDW did not show any measurable dissociation and 
hence lysozyme was absent in the supernatant. This observation further confirms the 
presence of ionic interaction between lysozyme and DS in the HIP complex. This sort of 
behavior was also reported in the literature by other investigators [98].  
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Figure 23: Dissociation of lysozyme from HIP complex in presence of buffers with different 
NaCl concentrations 
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The presence of electrostatic interaction between amino group and sulphate group 
was further confirmed by FTIR. Previously, FTIR analysis was also performed by other 
investigators to characterize this sort of interaction between amino group and sulphate group 
[102, 158, 159]. Due to complexities of an FTIR spectrum, we could not identify peak shift 
associated with the amino groups of lysozyme which interacted with sulphate group of DS. 
Instead we followed interactions of sulphate group of DS.  Characteristics peaks of sulphate 
group of DS in IR region are as following: (A) 802 cm
-1 
: S-O-S vibration  (B)1017 cm
-1
: 
symmetric SOO
- 
stretching vibration and  (C) 1225 cm
-1
: asymmetric SOO
- 
stretching 
vibration (Figure 24). Appearance of these peaks in the IR spectra was close to previously 
published results [102, 158, 159]. In the FTIR spectra of HIP complex, intensity of all the 
characteristics peaks of sulphate group was significantly reduced compared to free DS 
(Figure 24). This result clearly showed that sulphate group of DS was ionically complexed 
with the amino group of basic amino acid.  
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Figure 24: FTIR spectra of lysozyme (A) dextran sulphate (B) and HIP complex (C)
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An important goal of the present study was to investigate effect of HIP complexation 
on the enzymatic activity of lysozyme. During HIP complexation, lysozyme-DS complex 
precipitates from the solution. During the precipitation, it is quite possible that lysozyme may 
lose its enzymatic activity due to irreversible aggregation. Since DS interacts extensively 
with the protein molecule, the probability of protein denaturation and irreversible 
conformational change is even higher. Therefore, after dissociation of HIP complex, we have 
recovered lysozyme and measured its enzymatic activity. Further, we compared it with the 
enzymatic activity of freshly prepared solution of lysozyme. Our result confirms that there 
was not any statistically significant difference in the activity of freshly prepared lysozyme 
solution and the lysozyme obtained after dissociation from the HIP complex (Figure 25). We 
believe that during the formation of HIP complex, lysozyme may undergo conformational 
change. However, after dissociation from the HIP complex, it regains its native conformation 
and hence its enzymatic activity was not affected. This study further rules out the possibility 
of irreversible aggregation during precipitation of HIP complex.    
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Figure 25: Evaluation of an enzymatic activity of lysozyme after dissociation from HIP 
complex and comparison with enzymatic activity of freshly prepared solutions of lysozyme 
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We have successfully prepared nanoparticles by spontaneous emulsion solvent 
diffusion method using PLGA 85:15 as polymer. PLGA 85:15 was chosen as a polymer 
compared to other grades of PLGA such as PLGA 50:50 and PLGA 65:35 because of its 
highest lactide content which makes it hydrophobic in nature. We hypothesize that by 
employing PLGA 85:15 as a polymer, hydrophobic interaction between polymeric matrix 
and HIP complex could be maximized. We have employed DMSO as a solvent which is 
widely used for protein based molecules including lysozyme [98]. There were three major 
reasons behind the selection of this method to prepare nanoparticles. First of all, this method 
is devoid of organic solvent such as methylene chloride and physical stress such as sonication 
which often denatures the lysozyme [155]. Secondly, DMSO acts as a scavenger of free 
radicals and hence it enhances the stability of protein molecules. Finally, solubility related 
issues associated with HIP complex in other organic solvents. Solubility of HIP complex in 
any solvent depends on various parameters including nature of the complexing agent, 
polarity of solvent and pH of buffer solution containing macromolecule before preparation of 
HIP complex. Solubility related issues associated with HIP complex may also restrict the use 
of various methods which can be employed to prepare nanoparticles. Other investigators 
have employed solid in oil in water (S/O/W) emulsion method of nanoparticle preparation to 
overcome this solubility related issue of HIP complex. However, this method still involves 
treatment of protein molecule with organic solvents and sonication which could denature the 
protein such as lysozyme. 
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We have successfully prepared nanoparticles using different ratios of PLGA 85:15. 
Interestingly, we observed significant increase in the size of nanoparticles, as we employed 
higher amounts of PLGA to prepare nanoparticles. Size of the nanoparticles was 220±18 nm; 
427.6±28.3 nm and 541.6±63.1 nm when the ratio of HIP complex to PLGA 85:15 was 1:5, 
1:10 and 1:15, respectively (Table 12). At the ratio of 1:20, we could not prepare any 
nanoparticles. Once we started infusing DMSO solution into the external phase (1% 
poloxamer solution), polymer precipitated instantaneously resulting in large aggregates. This 
sort of behavior was also reported in the past by other investigators who have observed this 
phenomenon using other solvents and non solvents during nanoparticle preparation [160]. 
This could be due to higher intrinsic viscosity of DMSO solution which contained 
significantly higher amounts of polymer.  
 
Table 12: Particle size and entrapment efficiency of various batches of nanoparticles 
 
116 
 
 We also studied entrapment efficiency of lysozyme in the different batches of 
nanoparticles. We observed increase in the entrapment of the lysozyme as we increased the 
amount of PLGA used in the preparation of nanoparticles. When the ratio of HIP complex to 
PLGA 85:15 was 1:5, 1:10 and 1:15, entrapment efficiency of lysozyme in nanoparticles was 
38.8 ±9.1, 72.81±7.90 and 96.52±10.23 % respectively (Table 12). This could be explained 
because as we increased the polymer content, hydrophobic interactions with HIP complex 
increased simultaneously. This could result in higher entrapment of lysozyme in 
nanoparticles. We also performed SEM analysis to study morphology of nanoparticles. Our 
result clearly shows that nanoparticles did not have a clear round shape and smooth surface 
(Figure 26). Instead they reveal irregular and asymmetric morphology. This could be due to 
lack of sonication during preparation of nanoparticles. This sort of morphology of 
nanoparticles was also observed by other investigators previously who have prepared 
nanoparticles without using sonication [161].    
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Figure 26: Scanning electron microscopic image of polymeric nanoparticles encapsulating 
lysozyme (lysozyme:PLGA::1:5) 
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We also carried out XRD study to understand if the HIP complexation or nanoparticle 
preparation has altered the crystal structure of the protein. As shown in Figure 27, lysozyme 
exhibited very little crystallinity. This observation was also consistent with the results 
reported by other investigators in the past [162].  Figure 27 also represents the XRD pattern 
of HIP complex and various batches of nanoparticles. It is clear from our result that neither 
HIP complexation nor nanoparticle preparation has significantly altered crystal structure of 
lysozyme.  
 
Figure 27: X-ray diffractogram of lysozyme, dextran sulphate, HIP complex, PLGA, and 
different batches of nanoparticles 
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Finally, we studied the release of lysozyme from the nanoparticles (ratio of 
lysozyme:polymer 1:5). We have observed the sustained release of lysozyme from 
nanoparticles for almost 28 days with minimal burst effect (≈ 20% in first 2 days) (Figure 
28). We hypothesize several mechanisms for sustained release behavior of lysozyme from 
nanoparticles. First reason could be slow degradation of PLGA 85:15 and strong 
hydrophobic interactions of HIP complex with polymeric matrix. Moreover dissociation of 
lysozyme from the HIP complex was a slow process. As mentioned earlier, lysozyme was 
entrapped in the hydrophobic form in polymeric matrix and dissociation of lysozyme from 
the HIP complex was mainly dependent on the ionic strength of the surrounding medium. 
Since, the NaCl concentration in the releasing medium was ≈ 137 mM, dissociation of 
lysozyme occurred slowly from the complex. Finally, diffusion of the lysozyme in the form 
of HIP complex would occur slowly than free lysozyme from the polymeric matrix. Hence, 
this approach may provide significant advantages in terms of sustaining the release of a 
protein molecule from the polymeric matrix of nanoparticles. Currently, we are studying the 
HIP complexation of lysozyme with different molecular weights of DS. We are also 
investigating the effect of different molecular weights of DS on the release of lysozyme from 
polymeric matrix (data not included). Further, we are also studying effect of ionic strength of 
media and osmotic pressure on release of lysozyme from nanoparticles. In future, we also 
intend to study and calculate diffusion and dissociation rate constant for HIP complex.  
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Figure 28: In vitro release of lysozyme from PLGA nanoparticles (lysozyme:PLGA:: 1:5) 
121 
 
Finally, enzymatic activity of all the release samples was also measured and 
compared with the enzymatic activity of freshly prepared solutions of lysozyme. Results of 
this experiment are shown in Figure 29. This data clearly indicate that enzymatic activity of 
lysozyme was not affected during encapsulation and release from polymeric matrix of 
PLGA. This data also explains our previous result of XRD study, which confirmed that the 
amorphous form of lysozyme was preserved during HIP complex formation and also within 
polymeric matrix of nanoparticles.  
Figure 29: Evaluation of an enzymatic activity of lysozyme after released from nanoparticles 
and comparison with enzymatic activity of freshly prepared solutions of lysozyme 
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Conclusion  
We successfully prepared and characterized HIP complex of lysozyme using, dextran 
sulphate, a sulphated polysaccharide as a complexing agent. We observed a linear 
relationship between amounts of dextran sulphate added and formation of HIP complex. 
Characteristics of HIP complex formed using a polymer differs from characteristics of HIP 
complex formed using a surfactant. Electrostatic interactions seem to play a major role in the 
formation of HIP complex. Presence of electrostatic interactions was confirmed by rapid 
dissociation of lysozyme from HIP complex and also by FTIR studies. Nanoparticles were 
successfully prepared using spontaneous emulsion solvent diffusion method and 
characterized with respect to size and surface morphology. Entrapment of lysozyme was 
found to be increased as higher amount of PLGA was employed in the preparation of 
nanoparticles. XRD studies revealed that native form of lysozyme was preserved after 
formation of HIP complex and also within polymeric matrix of nanoparticles. Nanoparticles 
have shown to sustain the release of lysozyme without significant burst release. Enzymatic 
activity of lysozyme was not affected due to HIP complexation and also after releasing from 
polymeric matrix of nanoparticles. HIP complexation using a polymer may also be employed 
to formulate sustained release dosage forms for other large molecules including antibodies. 
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CHAPTER 7 
ENCAPSULATION OF PROTEIN-POLYSACCHARIDE HIP COMPLEX IN 
POLYMERIC NANOPARTICLES 
Rationale:  
Protein based therapeutics such as antibodies, blood products and vaccines have 
gained a wide acceptance in the past decade to treat a variety of disorders[145]. Development 
of a nanoparticulate based dosage form of these molecules is still considered as a major 
challenge by scientists in the drug delivery field. Single emulsion method (O/W) and double 
emulsion method (W/O/W) are the most widely used conventional methods to prepare 
nanoparticles. However, these methods employ sonication and organic solvents to prepare 
nanoparticles. Protein based therapeutics have shown rapid denaturation and conformational 
change due to sonication and exposure to organic solvents Protein based molecules may 
aggregate and eventually lose their biological activity due to physical and chemical stresses 
observed during formulation development e.g., exposure to organic solvents and sonication. 
These molecules may also denature or lose their biological activity during storage and 
lyophilization [151, 154, 163]. Sonication is employed to ensure homogeneous dispersion of 
an emulsion. However sonication may result in large pressure and temperature gradient 
which cause denaturation and aggregation of protein molecule [155]. Moreover, sonication 
also causes generation of high shear force and free radicals which cause protein denaturation 
[155]. Organic solvents preferentially interact with the non-polar amino acids of the protein 
via hydrophobic interactions. Normally, these non-polar amino acids are present in the core 
of the protein structure. Hence, in presence of organic solvents, the native structure and 
conformation of protein are usually altered. This might result in loss of biological activity of 
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a protein molecule.  Another crucial formulation related limitation of protein molecules is 
their hydrophilicity. Due to hydrophilic nature of these molecules, they often partition poorly 
in the polymeric matrix during encapsulation resulting in minimal loading in nanoparticles 
[145]. Due to poor loading of these molecules, a higher amount of polymer is needed to 
develop a formulation. Poly lactic-co-glycolic acid (PLGA) is one of the most widely 
employed biocompatible and biodegradable polymers to prepare nanoparticles. However, 
higher amounts of PLGA have shown detrimental effect on the stability of protein molecules. 
Protein molecules are also found to be unstable in the presence of lactic acid and glycolic 
acid which are degradation products of poly lactic-co-glycolic acid (PLGA) [149-151].  
Hydrophobic ion pairing (HIP) complexation approach has gained wide acceptance in 
the delivery of peptide and protein based therapeutics [93, 94, 96, 98, 102]. In this approach, 
ionizable functional groups of a drug molecule are ionically complexed with the surfactant or 
a polymer having oppositely charged functional groups. The resulting drug-polymer or drug-
surfactant complex is known as HIP complex. Since the hydrophilic drug molecule exists in 
the form of a complex which is hydrophobic, its partition in the polymeric matrix can be 
significantly enhanced during encapsulation [79, 94]. Protein and polymer (used for HIP 
complexation) primarily interact due to ionic interactions during formation of HIP complex. 
Hence, the complex can be dissociated in presence of excess of the oppositely charged ions. 
Further, HIP complexation would obviate the use of any covalent modification in protein 
molecules to make them more hydrophobic in nature. These covalent modifications may also 
result in the irreversible loss in the biological activity of these molecules. Various studies 
have been performed in the past to understand the nature of protein-surfactant interaction. 
HIP complexation approach has been studied with various peptide and protein based 
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molecules such as leuprolide, insulin, mellitin, lysozyme etc [93, 94, 98, 102]. HIP 
complexation of protein based therapeutics has resulted in overcoming various issues 
associated with delivery of protein molecules such as bioavailability and stability [98, 99]. 
Moreover, HIP complexation has also shown to impart conformational stability to the protein 
molecule [98].    
HIP complexation approach has been mainly employed to peptides and small protein 
molecules mentioned earlier. HIP complexation of large protein molecules is a challenging 
task due to two reasons. First, larger the molecule, larger the number of groups with opposite 
charges that may hinder the HIP complexation process. So far, basic amino acids have been 
employed (mainly lysines and arginines) to form HIP complex using negatively charged 
surfactant molecules. However, in large protein, aspartic acid and glutamic acid are also 
present in the large number on the surface which would repeal the negatively charged 
complexing molecules. Second, in a larger molecule, charge density plays a very crucial role 
as well. In large protein, there is usually more surface area per charge than for a small protein 
molecule. Hence, selection of a surfactant or polymer with appropriate chain lengths plays a 
very crucial role in formation of HIP complex in case of macromolecules. Activity of protein 
molecule also depends on its secondary and tertiary structure. These structures are stabilized 
by various non-covalent interactions such as electrostatic interactions, hydrogen bonds, Van 
der waals forces and hydrophobic interactions [89, 152, 153]. Hence, an ideal complexing 
agent should be employed which would not perturb the secondary and tertiary structure of the 
protein. So far, various surfactants molecules have been used to prepare HIP complex. In the 
present study, we have investigated HIP complex formation phenomenon by employing 
dextran sulphate, a polysaccharide molecule with bovine serum albumin (BSA).     
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We have chosen BSA as a model protein for HIP complexation. BSA is a 66.3 Kda 
molecule. It is globular in shape and has been widely used as a model protein in various 
studies before [165, 166] . We have chosen dextran sulphate (Molecular weight: 9-20KDa), a 
polysaccharide as a complexing polymer. We prepared and characterized HIP complex of 
BSA using dextran sulphate. Solid in oil in water (S/O/W) emulsion method has been 
employed to prepare nanoparticles. Nanoparticles were characterized with respect to particle 
size and surface morphology. Finally, we studied the effect of HIP complexation and 
nanoparticle preparation on the secondary and tertiary structure of BSA using circular 
dichroism and intrinsic fluorescence assay, respectively.  
Materials and method 
Materials: Bovine serum albumin, dextran sulfate sodium salt (molecular weight 9000-20000 
da), Poly (DL-lactide-co-glycolide) (PLGA 85:15, molecular weight of 50,000-75,000 da), 
bicinchoninic acid (BCA), and copper sulphate were purchased from Sigma Aldrich. Micro-
BCA protein assay kit was purchased from Thermo scientific. All the solvents and other 
reagents of analytical grade were purchased from local suppliers and used as such without 
any purification. Double distilled water (DDW) was used throughout the entire study.  
 
Preparation of HIP complex of BSA and DS 
Stock solutions of BSA and DS were prepared in citrate buffer pH 4.4 and DDW, 
respectively. BSA consists of various basic amino acids (60 lysines and 26 arginine amino 
acids) while DS contains 2.3 sulphate groups per glucosyl residue. HIP complex was formed 
instantaneously as both the aqueous solutions were mixed in particular ratio and then 
vortexed.  
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Effect of different molar ratios of BSA to DS on HIP complex formation   
Stock solutions of BSA and DS were prepared as mentioned in the earlier section. 
HIP complexes were prepared in different molar ratios of BSA/DS. The molar ratios studied 
were 0.29, 0.58, 0.87 and 1.15. These molar ratios represent the addition of different amounts 
of DS into earlier prepared BSA solution (5mg/mL in pH 4.4 citrate buffer). Once formed, 
HIP complex was vigorously vortexed for 3 minutes followed by centrifugation at 10000 
RPM for 10 minutes to separate supernatant. Uncomplexed BSA was measured in the 
supernatant using BCA assay. Percentage of complexed BSA was calculated using the 
following equation. 
% complexed BSA = [(Initial amount of BSA – amount of BSA in supernatant)/ Initial 
amount of BSA)] *100    (Eq. 3.) 
 
Dissociation of BSA from HIP complex  
Dissociation of BSA from HIP complex was studied to characterize the nature of 
interaction between BSA and DS. Freeze dried HIP complex containing 5 mg of BSA was 
accurately weighed and incubated in presence of DI water and aqueous solution containing 
10 mM Na2HPO4. These solutions were vortexed and kept for equilibrium for 3 hrs at room 
temperature. After 3 hrs, these solutions were subjected to centrifugation and supernatant was 
collected. The concentration of dissociated protein in the supernatant was then measured with 
BCA assay.  
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FTIR study 
FTIR analysis of BSA, DS and HIP complex was carried out with an infrared 
spectrophotometer (Perkin-Elmer, Waltman, MA). The samples were brought into intimate 
contact with the diamond crystal by applying a loading pressure. The samples were casted on 
diamond crystal top-plate of Attenuated Total Reflectance (ATR) accessory and scanned 
between 650 -1800 cm
-1
. Spectra obtained using this device represents the average of 32 
individual scan possessing a spectral resolution of 4 cm
-1
. 
 
Preparation of nanoparticles  
PLGA 85:15 was used as a polymer to prepare the nanoparticles. Nanoparticles were 
prepared by using solid in oil in water (S/O/W) emulsion method published earlier with 
minor modifications [79]. Briefly, five mg of BSA in complex form was used for preparation 
of nanoparticles. PLGA 85:15 was dissolved in methylene chloride. Two different ratios of 
BSA: PLGA 85:15 (1:5 and 1:10) were employed to prepare the nanoparticles. PLGA 
solution was gradually added to the earlier prepared HIP complex. Total volumes of 
methylene chloride and vortexing time were optimized to obtain S/O dispersion. About 4-5 
mL of methylene chloride was required to completely disperse the HIP complex. Sonication 
was performed for about ≈ 3 minutes using tip sonicator (Fisher 100 Sonic dismembrator, 
Fisher Scientific) at power output of 25-30 W to obtain the fine S/O dispersion. To this S/O 
dispersion kept in ice, external aqueous phase (30 mL, 1% PVA) was added followed by 
further sonication for ≈ 3-4 minutes under similar conditions.  This procedure resulted in 
S/O/W nanoemulsion.  The nanoemulsion was kept on a shaker bath at room temperature for 
15-20 minutes followed by complete evaporation of methylene chloride using Rotavap. 
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Following evaporation, the nanodispersion was centrifuged for 50 minutes at 22,000g. 
Nanoparticles were washed two times with DI water to remove any surface bound BSA and 
PVA followed by freeze drying. Similarly, blank nanoparticles were also prepared by 
employing only polymer (PLGA 85:15) in similar amounts.  
 
Characterization of nanoparticles 
Entrapment efficiency of nanoparticles: Entrapment efficiency was measured using 
an earlier published protocol [165, 166] with minor modifications. Briefly, 1mL of 
nanosuspension was added to 9 mL of methylene chloride solution. This solution was then 
vortex mixed for 10-15 minutes to dissolve the polymer completely. Later, this solution was 
subjected to centrifugation which resulted in formation of a protein pellet. Methylene 
chloride was carefully separated and the pellet was dissolved in 10 mL of PBS buffer. 
Concentration of BSA in the aqueous phase was measured using Micro-BCA assay. 
Absorbance from the samples were corrected by subtracting the absorbance from blank 
nanoparticles prepared using PLGA 85:15.  
 
Particle size measurement 
 
The mean particle size and polydispersity of the nanoparticles were measured by DLS 
(Brookhaven Inst. Co., USA) at an operating angle of 90° and at a temperature of 25 °C. A 
dilute sample of the nanosuspension was taken for particle size analysis and at least three 
measurements of each batch were carried out.  
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SEM and TEM analysis 
For SEM analysis, freeze dried specimen was applied on a sticky carbon film 
positioned on an aluminum stub. Specimens were sputter coated with gold-palladium and 
observed with the field-emission SEM XL30 (FEI, Hillsboro, OR). For TEM study, a drop of 
nanosuspension was deposited on TEM cooper grid with carbon film. Following drying, it 
was observed under Phillips TEM CM12 (FEI, Hillsboro, OR). 
 
Evaluation of secondary structure of BSA after dissociation from HIP complex and release 
from nanoparticles using circular dichroism 
HIP complex was dissociated in presence of 1 mL of 10 mM Na2HPO4 solution and 
free BSA was quantified using BCA assay. Similarly, earlier prepared PLGA nanoparticles 
were incubated in the presence of 1 mL of 10mM Na2HPO4 solution and kept overnight. BSA 
released from nanoparticle was quantified on the following day using BCA assay. Finally 
BSA solution was freshly prepared in 10mM Na2HPO4  solution and used as a control. Final 
concentration of each sample was adjusted to 0.05 mg/mL. Circular dichroism (CD) spectra 
was collected using Jasco 720 spectropolarimeter at room temperature. The spectra of all the 
samples were collected over a range of 200-250 nm using a cuvette of 1 cm path length at a 
scan speed of 20 nm/min. Data were further processed for blank subtraction, noise reduction 
and an average of three signals was recorded. All the CD measurements are reported as 
ellipticity (θ, mdeg).  
131 
 
 
Evaluation of tertiary structure of BSA after dissociation from HIP complex and release from 
nanoparticles using intrinsic fluorescence assay  
Fluorescent measurements were carried out at room temperature with fluorescence 
spectrophotometer (Photon Technology International). Standards and samples were prepared 
in 10mM Na2HPO4 solution (final BSA concentration was adjusted to 0.1 mg/mL). We 
compared fluorescence spectra of standard with BSA obtained after dissociation from HIP 
complex and BSA released from nanoparticles samples. All samples were excited at a 
wavelength of λex 295 nm and emission spectra was collected between 310-400nm. λex 295 
nm was chosen to selectively excite tryptophan amino acid of BSA. Quartz cells (12.5 L x 
12.5mm W) having 3 mL of sample capacity was used for measurement. Fluorescent 
emission spectra were recorded and are displayed in terms of relative fluorescence. 
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Result and Discussion 
Proteins and peptides belong to a rapidly growing class of therapeutic drugs with 
more than 200 biopharmaceuticals in the market and many more at different stages of 
development. Design of nanoparticle based formulations of protein based therapeutics has 
become a major challenge for the drug delivery scientists because of their poor encapsulation 
in polymeric matrix and rapid denaturation in the presence of organic solvent and sonication 
[147, 148]. HIP complexation based approach has been widely explored to deliver peptide 
and protein based therapeutics. HIP complexation can overcome various stability related 
issues, enhance drug loading in nanocarriers and improve drug permeation across biological 
membrane [93, 94, 96-98, 102]. So far, HIP complexation based approach has been only 
studied with small peptide and protein based therapeutics. Hence, BSA was selected as a 
model protein in the present study because of the higher molecular weight (66.3 KDa). The 
structure of BSA is also well known and it has also been employed as a model protein in 
previous studies by various investigators. 
Isoelectric point (PI) of BSA is ≈ 4.5 and it is composed of various basic amino acids 
(60 lysine and 26 arginines). Being hydrophilic in nature, these amino acids are mostly found 
on the surface of the protein. Amino groups of these amino acids would be protonated based 
on pH of the surrounding medium. Our earlier attempts to form HIP complex of BSA at pH 
4.5 with DS failed. This could be due to repealation of the negative charge of the sulphate 
group (from DS) with the carboxylic group (from aspartic acid and glutamic acid) of BSA. 
Hence, we have slightly modified the pH of BSA solution and prepared stock solution of 
BSA in pH 4.4 citrate buffer. At this pH, HIP complex was formed immediately once we 
mixed both aqueous solutions of BSA and DS.
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We also studied the effect of molar ratios of BSA/DS on HIP complex formation. We 
calculated the molar ratios based on the total number of lysine amino acids present on the 
surface of BSA (60 lysine amino acid). The following molar ratios of BSA/DS were prepared 
(0.29, 0.58, 0.87 and 1.15). Theoretically, each molar ratio represents the amount of DS 
added to bind with 15, 30, 45 and 60 basic amino acids of BSA. Figure 30 shows the 
complexation of BSA with DS at different molar ratios. An excellent correlation was 
observed between increment in the molar ratio of BSA/DS with the amount of BSA 
complexed with DS (Figure 30). In fact at the molar ratio of 1.15, more than 90% of BSA 
was ionically complexed with DS. This data clearly indicates the involvement of basic amino 
acids in the formation of HIP complex.  
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Figure 30: Effect of molar ratios of bovine serum albumin:dextran sulphate on HIP 
complex formation 
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 We hypothesized ionic interactions as a driving force for complexation of BSA with 
DS. In order to confirm our hypothesis, we performed dissociation studies of the HIP 
complex in presence of excess of oppositely charged ions (HPO4
-2
). Our results of this 
experiment are shown in Figure 31. When HIP complex was incubated in DI water, we did 
not observe any dissociation of BSA from HIP complex. This could be due to absence of any 
ions in DI water. However when we incubated HIP complex in the presence of 1 mL of 
10mM Na2HPO4 solution, entire HIP complex was dissociated and solution became clear. 
These data further confirms the presence of ionic interaction between amino group of basic 
amino acids and sulphate group of DS. Dissociation of HIP complex in presence oppositely 
charged ions is also reported in the literature by other investigators [79, 98]. 
 
 
 
 
 
 
 
 
 
 
Figure 31: Dissociation of bovine serum albumin from HIP complex in the presence of 
distilled water and 10 mM Na2HPO4 solution 
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We also performed FTIR study to understand the nature of interaction between amino 
group of basic amino acids and sulphate group of DS. Previously, FTIR analysis was 
performed by other investigators to characterize this sort of interaction between amino group 
and sulphate group [102, 158, 159]. Due to complexities of a FTIR spectrum, we did not 
follow peak shift associated with the amino groups of BSA which interacted with sulphate 
group of DS.  Instead, we studied the interaction of sulphate group of DS in IR region. 
Following are the characteristics peaks of sulphate group of DS which we observed in IR 
region: (A) 802 cm
-1
: S-O-S vibration (B)1017 cm
-1
: symmetric SOO
- 
stretching vibration 
and (C) 1225 cm
-1 
: asymmetric SOO
- 
stretching vibration. Appearance of these peaks in the 
IR spectra was close to previously published results. We hypothesized that in case of ionic 
interaction between amino group and sulphate group, the peak intensity of the sulphate group 
in the IR region would reduce significantly. Results of this study are shown in Figure 32. 
These results clearly indicate the significant reduction in the peak intensities of sulphate 
group in the IR region which again confirmed the presence of ionic interaction between 
amino group and sulphate group.  
137 
 
 
Figure 32: FTIR spectra of bovine serum albumin (A), dextran sulphate (B) and HIP complex 
(C) 
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Finally, we prepared nanoparticles of BSA in HIP complex form using S/O/W 
emulsion method. This method of preparation offers significant advantages compared to 
conventional methods of nanoparticles preparation such as single and double emulsion 
method. In the conventional methods of preparation, protein is initially dissolved in an 
aqueous phase and later emulsified in the presence of an organic phase using sonication. 
Most of the protein denaturation occurs during this stage of nanoparticle preparation due to 
water-organic phase interface, excessive stress arising during sonication process and 
generation of free radicals. S/O/W emulsion method had an additional advantage because in 
this method protein-polysaccharide powder was employed in the preparation of nanoparticles 
instead of protein in the solution form. Moreover, in the powder form, kinetic mobility of the 
protein is restricted than its liquid form [165, 166]. We also hypothesized that complexation 
with DS would not only restrict conformational flexibility of BSA but also impart additional 
steric shielding to protein molecule. We optimized the total volume of organic solvent used 
and sonication time to prepare nanoparticles. Prepared nanoparticles were also characterized 
with respect to particle size (Table 1). Particle size of both the batches ranged between 150-
200nm. SEM and TEM study of nanoparticles were performed to study the surface 
morphology. The results of these studies are shown in Figure 33 and 34 respectively. These 
results confirmed that particles were smooth in surface and spherical in shape.  
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Figure 33: Scanning electron microscopic image of polymeric nanoparticles encapsulating 
bovine serum albumin (bovine serum albumin:PLGA :: 1:5) 
 
 
 
 
 
 
Figure 34: Transmission electron microscopic images of nanoparticles encapsulating bovine 
serum albumin (bovine serum albumin:PLGA::1:5) 
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One of the important goals of the present study was to achieve higher drug loading of 
BSA in nanoparticles by employing minimal amounts of polymer (PLGA 85:15). We have 
prepared nanoparticles by employing two different ratios of protein: PLGA (1:5 and 1:10). 
The entrapment of BSA in nanoparticles was more than 65% in both the cases (Table 13). 
This result clearly shows a significant loading of BSA in polymeric matrix of PLGA. We 
observed higher entrapment of BSA in nanoparticles as we increased the amount PLGA 
employed during preparation. This could be because enhanced hydrophobic interactions of 
BSA in HIP complex form with PLGA polymer. Due to these hydrophobic interactions, 
partition of BSA (in HIP complex form) in the polymeric matrix of PLGA was also 
significantly enhanced.  
Table 13 : Particle size, polydispersity and entrapment efficiency of different batches of 
nanoparticles 
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We also studied the effect of HIP complexation and nanoparticle preparation on 
secondary structure of BSA by analyzing the CD spectra. It is a well known fact that various 
weak physical interactions such as electrostatic interactions, hydrogen bonds, Van-der-waals 
forces and hydrophobic interactions stabilize the secondary structure of the protein. During 
HIP complex formation, DS interacted extensively with BSA. So, it is quite possible that DS 
might have changed the native conformation of BSA. Similarly, during nanoparticle 
preparation, we employed organic solvents and sonicated powder form of BSA-DS complex 
with organic solvents. These processes could denature BSA also. CD analysis was performed 
to understand the impact of these formulation factors on secondary structure of BSA. Freshly 
prepared BSA in 10mM Na2HPO4 solution was selected as a control. Figure 35 represents the 
CD spectra of standard BSA solution, BSA obtained after dissociation of HIP complex and 
BSA released from both the batches of nanoparticles. Our results clearly show a significant 
overlap in peak shape throughout the region we studied. This data also confirms that the 
secondary structure of BSA was not changed due to HIP complexation or due to treatment 
with organic solvent and sonication. Enhanced stability of BSA towards organic solvents and 
sonication could be explained by a couple of reasons. First, HIP complexation might have 
provided conformation stability and steric shielding to protein molecule. Moreover by 
employing S/O/W emulsion method, the chances of protein denaturation were further 
minimized compared to conventional method such as W/O/W emulsion method. This is 
because in S/O/W emulsion method, protein molecules were being encapsulated in the solid 
state compared to W/O/W emulsion method where liquid form of protein was employed. In 
the solid state, water-organic phase interface was also absent which is known to have a 
detrimental effect on the stability of the protein.  
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Figure 35: Circular dichroism spectra of freshly prepared solution of bovine serum albumin, 
bovine serum albumin obtained after dissociation from HIP complex, and bovine serum 
albumin released from nanoparticles  
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Finally, we compared the intrinsic fluorescence spectra of freshly prepared BSA with 
BSA obtained after dissociation from HIP complex and BSA released from different batches 
of nanoparticles. BSA contains a buried tryptophan amino acid in its hydrophobic core. 
Fluorescence of tryptophan is very sensitive to polarity of its surrounding medium [167]. 
Change in the fluorescence intensity, wavelength of maximum fluorescence emission and 
quantum yield are accepted as indicators to study tertiary structure of protein. Results of this 
study are shown in Figure 36. It is very clear from our data that intensity and wavelength of 
maximum fluorescence (335nm) were similar in all the samples. This data again confirms 
that tertiary structure and native conformation of BSA have not been changed following 
dissociation from HIP complex and also after released from nanoparticles. This result also 
corroborates with our previous CD spectra results where we have observed no significant 
change in secondary structure of BSA due to HIP complexation and nanoparticle preparation. 
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Figure 36: Intrinsic fluorescence assay of freshly prepared solution of bovine serum albumin, 
bovine serum albumin obtained after dissociation from HIP complex, and bovine serum 
albumin released from nanoparticles 
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Conclusions  
This is the first study which shows the feasibility to form HIP complex of a large 
molecules such as BSA using dextran sulphate as a complexing polymer. Our study confirms 
the involvement of basic amino acids in the formation of HIP complexation. Dissociation of 
HIP complex in the presence of excess of oppositely charged ions (HPO4
-2
) and FTIR studies 
have revealed the presence of ionic interactions between amino groups of the basic amino 
acids and sulphate groups of dextran sulphate. We successfully prepared and characterized 
nanoparticles of BSA in HIP complex form using S/O/W emulsion method. SEM and TEM 
studies revealed smooth surface and spherical shape of nanoparticles. We obtained 
significant entrapment of BSA in nanoparticles with employment of less amounts of PLGA 
85:15. Finally, CD analysis and intrinsic fluorescence data revealed that secondary and 
tertiary structure of BSA was not affected due to HIP complexation and nanoparticle 
preparation. HIP complexation approach can also be employed to enhance loading of large 
proteins and antibodies based molecules in colloidal dosage forms. 
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CHAPTER 8 
SUMMARY AND RECOMMENDATIONS 
Summary 
Delivery of dexamethasone for posterior segment ocular diseases is a challenging 
task. We have hypothesized and employed transporter targeted prodrug approach to 
overcome various delivery related challenges of dexamethasone such as poor aqueous 
solubility and permeability, lack of targetability and frequent injections via intravitreal route. 
Our long term goal is to administer hydrophilic, water soluble prodrugs of dexamethasone 
via transscleral/subconjunctival route. Following transscleral/subconjunctival administration, 
these molecules can cross sclera and recognized by peptide transporter present on basolateral 
side of the retina. Due to recognition by peptide transporters, a higher concentration of drug 
can be achieved eventually in the inner retinal tissue. We successfully synthesized 
dexamethasone prodrugs (valine-valine-dexamethasone and glycine-valine-dexamethasone) 
and evaluated their physicochemical properties. Both prodrugs were recognized by peptide 
transporters present on MDCKII-MDR1 cells. Solubility of prodrugs was significantly 
enhanced than the parent drug (50-fold enhancement for valine-valine-dexamethasone and 
35- fold enhancement for glycine-valine-dexamethasone). Solubility enhancement may lead 
to administration of a higher dose of prodrug molecule via transscleral/subconjunctival route. 
Though a dramatic enhancement in the solubility of prodrugs was observed, their permeation 
across sclera and RCS tissues was not affected. Transporter targeted prodrug strategy was 
successfully employed to improve physicochemical properties and overcome delivery related 
issues of dexamethasone. Further, this dissertation also lead to development of a 
nanoparticulate based sustained release formulation of valine-valine-dexamethasone which 
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can be administered via subconjunctival route. Being hydrophilic in nature, valine-valine-
dexamethasone readily leached out in the external aqueous medium during preparation of 
nanoparticles and hence partitioned poorly into the polymeric matrix resulting in minimal 
entrapment in nanoparticles. Hence, hydrophobic ion pairing (HIP) complexation of the 
prodrug was employed with dextran sulphate as a complexing polymer. A novel, solid in oil 
in water (S/O/W) emulsion method was employed to encapsulate the prodrug in HIP 
complex form in poly(lactic-co-glycolic acid) (PLGA) matrix. Nanoparticles were 
characterized with respect to size, zeta potential, crystallinity of entrapped drug and surface 
morphology. A significant enhancement in the entrapment of the prodrug in nanoparticles 
was achieved. Nanoparticles were also found to sustain the release of the prodrug. Finally, a 
simple yet novel method was developed which can also be applicable to encapsulate other 
charged hydrophilic molecules such as peptides and proteins.  
Protein based therapeutics such as antibodies, blood products and vaccines have 
gained a wide acceptance in the past decade to treat a variety of disorders including in the 
treatment of ocular diseases. Development of a sustained release nanoparticulate based 
formulation of protein therapeutics has become a major challenge for the drug delivery 
scientists. Protein based therapeutics rapidly denature and lose their bioactivity in presence of 
organic solvents and stress arising from sonication during encapsulation process. Moreover, 
being hydrophilic in nature, their loading in polymeric matrix is also minimal. Hydrophobic 
ion pairing (HIP) complexation of protein drugs has become a popular approach to overcome 
many of above mentioned problems. Hence we developed a platform technology to 
encapsulate protein based molecules in nanoparticles using HIP complexation. We have 
prepared HIP complexes of two basic model proteins (lysozyme and bovines serum albumin) 
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using dextran sulphate as a complexing polymer. We have prepared and optimized HIP 
complex formation process of proteins with dextran sulphate. We observed a linear 
relationship between amounts of dextran sulphate employed and formation of HIP complexes 
of proteins. Dissociation of HIP complexes was observed in the presence of oppositely 
charged ions. FTIR analysis has revealed the presence of ionic interaction between basic 
amino acids of protein and sulphate groups of dextran sulphate. Nanoparticles of both protein 
molecules were prepared and characterized with respect to size, polydispersity and surface 
morphology. A significant enhancement in entrapment of both proteins was observed with 
minimal employment of PLGA polymer. Further, our data also confirmed that neither HIP 
complexation nor method of nanoparticle preparation had any effect on structure (secondary 
and tertiary structures of bovine serum albumin) and activity (enzymatic activity) of protein 
molecules. HIP complexation based approach may also be employed to formulate colloidal 
dosage forms for other protein molecules including antibodies which are often used in many 
diseases conditions. 
Recommendations 
Transporter targeted prodrug approach may serve as an alternative strategy to deliver 
drug molecules with poor solubility and permeability across ocular tissues. Hydrolytic 
enzymes responsible for the bioreversion of the dipeptide prodrugs are stereospecific and 
exhibits high affinity for L-isomers. Incorporation of single D-isomer at a particular position 
of dipeptide prodrug (LD and DL) retained the affinity towards the peptide transporter and 
improved its enzymatic stability. Hence, stereoisomeric prodrugs (L-valine-D-valine-
dexamethasone and D-valine-L-valine-dexamethasone) may exhibit higher stability in 
presence of enzymes than L-valine-L-valine-dexamethasone. Due to enhanced stability, these 
149 
 
prodrugs may also result in enhanced permeation across ocular tissues (sclera and retina-
choroid-sclera).  
HIP complexation based approach may also be used to enhance the encapsulation of 
various small hydrophilic and protein based molecules in other colloidal dosage forms such 
as micelles, liposomes etc. Physicochemical properties of HIP complex depend on various 
factors such as nature of drug molecule, size and structure complexing polymer, pH of 
complexation, presence of other additives etc. Hence, a HIP complex can be formed 
depending upon the requirement of delivery system. HIP complexation may provide 
shielding effect and hence can improve protein stability. Structural perturbations arising in 
presence of organic solvents and sonication may also be minimized during encapsulation 
process. Release of a drug molecule may be controlled based on the nature of the complexing 
polymer employed. Use of higher molecular weight polymer for complexation may sustain 
the release of the complexed drug than the polymer with small molecular weight. Since, 
protein molecules are more stable in complexed form, their propensity to undergo 
deamidation, oxidation and aggregation may reduce as well. Finally, HIP complexation may 
also stabilize protein molecule in presence of lactic acid and glycolic acid which are 
generated due to degradation of PLGA.   
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